US5595743A - Preparation of herbal medicines by using a multi-enzyme system, herbal medicines prepared and their uses - Google Patents

Preparation of herbal medicines by using a multi-enzyme system, herbal medicines prepared and their uses Download PDF

Info

Publication number
US5595743A
US5595743A US08/359,693 US35969394A US5595743A US 5595743 A US5595743 A US 5595743A US 35969394 A US35969394 A US 35969394A US 5595743 A US5595743 A US 5595743A
Authority
US
United States
Prior art keywords
herbal medicine
root
effect
enzyme
mash
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US08/359,693
Inventor
Wencai Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of US5595743A publication Critical patent/US5595743A/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/234—Cnidium (snowparsley)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Definitions

  • This invention relates to a process of preparing herbal medicines by using a multi-enzyme system and relates to herbal medicines made by the process and their pharmaceutical uses.
  • Herbal medicines have been used for treating various diseases in various countries for a very long period of time.
  • the preparations of herbal medicines have been developed in years.
  • a typical traditional method for example, used in China is a physical preparation method, such as, stirring-baking, decocting and parching.
  • a new method of preparing herbal medicines is desired by which herbal medicines have quicker therapeutical effect and lower toxicity and side effects.
  • One of the objections of the present invention is to provide a process for preparing herbal medicines in which a multi-enzyme system is used in treating raw materials.
  • Another objection of the present invention is to provide new herbal medicines prepared by using a multi-enzyme system which may be used in treating various diseases.
  • Another objection of the present invention is to provide new herbal medicines which have better solubility and higher therapeutical effect.
  • Another objection of the present invention is to provide a process for preparing herbal medicine at lower costs in which a multi-enzyme system is employed to increase the solubility of the herbal medicines by transferring large molecular materials into low molecular materials.
  • a process of preparing a herbal medicine comprises the steps of forming a mash from raw material, first finely grinding the mash so that the size of the suspension particles of the said mash is less than 50 ⁇ m, treating the ground material with biological enzymes to promote the hydrolysis of the said material in which the biological enzymes form a multi-enzyme system comprising cellulases, proteases, amylases, lipases and lysozymes, and sterilizing the enzymatic hydrolysis material.
  • the present invention relates also to the herbal medicines prepared by the above mentioned process and uses of these herbal medicines in the treatment of human and/or animal diseases.
  • the ratio of dissolution of effective medical composition of original medicine can greatly be increased due to the reinforcing treatment of solubility. It can be increased to nearly 100%, which facilitates processing and purification.
  • That high molecular materials, such as cellulose, protein, starch etc. can be conversed into oligosaccharide, oligopepitde, and saponin which can be very easily absorbed by human body, leads to inductive absorption.
  • the absorptivity of effective medical compositions can be increased to nearly 100% from 10-60% of traditional method.
  • the therapeutical effect is prominent and the effectual time is greatly shortened to be the same as that of western medicines.
  • Oligosaccharide, oligopeptide and saponin have effects in regulating human body's immunity and endocrine functions and can be used for immunity therapy in modem medicines. Therefore, a number of oligosaccharides and oligopeptides, existing in the Chinese herbal medicine preparations by the process of the present invention, can reinforce the effect, so that the effective dosages of Chinese herbal medicines may be reduced to 1/10- 1/200 of that in the traditional method.
  • the process of the present invention has no selectivity to raw materials, which adapts to any medicines from animal and plant resources.
  • RNA ribose nucleic acids
  • DNA deoxyribonucleic acids
  • enzymes secreted from cells can decompose diseased ribose nucleic acids and deoxyribonucleic acids, at the same time, can promote the synthesis of normal ribose nucleic acids and deoxyribonucleic acid and facilitate the synthetic speed (it is about 2-5 times faster than that under usual conditions).
  • Neogenesic cells can clear the foci as well as repair the structure and function of diseased tissues.
  • the herbal medicines of the present invention have a function of systematic therapy. That is to say that one particular herbal medicine can be used for treating all diseases in a particular anatomical system.
  • a process of preparing herbal medicines comprises treating a raw material with biological enzyme system that contains multi-biological enzymes to promote the hydrolysis of the said raw material. Before treated with the multi-enzyme system, the raw material is pre-treated in the following steps.
  • the raw material is crushed or beaten to form a mash by conventional processes, such as mechanical crushing or beating process.
  • the particles of the crushed or beaten raw material are small, making it easier to perform the next steps.
  • the average size of the said particles is about 600 meshes to about 2000 meshes.
  • the crushed or beaten raw material may also be soaked. In some instances, the soaked step may be taken place before the raw material is crushed or beaten, particularly when the raw material is drier. Generally speaking, moisture in the raw material is gradually lost during storing, and the longer the material is stored, the more moisture will be lost.
  • an adequate amount of water is added during the step of soaking in order to maintain the moisture content of the cracked raw material higher than 50%, preferably between 75% to 80%.
  • the time of soaking varies according to the degree of freshness of the raw material. The fresher the material is, the shorter it will be pre-soaked. Normally, the soaking time is 15 minutes to 36 hours.
  • the soaked material is then subject to first fine grinding.
  • the size of the suspended particles of the finely ground material is less than 50 ⁇ m.
  • the ground mash is then treated with biological enzyme to promote the hydrolysis of the material while stirred.
  • the biological enzyme used in the present invention is multi-enzyme system that comprises cellulases, proteases, amylases, lipases and lysozymes.
  • the multi-enzyme system may further comprises one or more of supplementary enzymes, such as hemicellulases, pectases, glucase peptidases, or peptichainases etc.
  • the activity. unit of the enzyme used is 20,000-10,000,000 IU/g and the specific activity concentration is about 1 to 1000 IU/g substrate.
  • the specific activity concentration of the enzyme system used is slightly increase.
  • the temperature of enzyme hydrolysis is about 20°-80° C. and the time of enzyme hydrolysis is from about 5 minutes to about 144 hours.
  • the enzyme-treated material may be subject to second finely grinding to give an average particle size of less than 5 ⁇ m in some cases.
  • the enzyme-treated material may or may not be filtered to eliminate the residues which depends on the desired form of a herbal medicine produced.
  • the material is filtered so that the particles of the filtered material are of the desired average sizes.
  • the enzyme-treated material filtered or not filtered, is then sterilized.
  • the sterilization of the present invention is carried out under a temperature about 50° C. or below.
  • the sterilizing step in the present invention involves using ultrafiltration or ultrasonic sterilizing method. Or both ultrofiltration and ultrasonic method are used.
  • the ultrasonic sterilizing method comprises killing the bacterium and enzyme and sterilizing the material while it is flowing through an ultrasonication apparatus.
  • the frequency of the ultrasonic waves suitable for use in the present invention is about 20-100 KHz, the power density is over 100 W/cm 2 , and the flow speed is about 1-25 m/s.
  • the multi-enzyme system used in the process comprises, by weight, 5-75% of cellulases, 5 to 50% of proteases, 5 to 50% of amylases, 1 to 20% of lipases, and 1 to 15% of lysozymes.
  • the multi-enzyme system may further comprise one or more supplementary enzymes, for example, 0 to 15% of hemicellulases, 0 to 30% of pectases; 0 to 10% glucase peptidases; and 0 to 10% of peptichainases.
  • the sterilization material may be adjusted to a suitable form for preparing a desired dosage form of a herbal medicine by conventional means such as, concentration in vacuum, and spray drying etc.
  • the desired dosage forms depend on the herbal medicines which are produced. Different herbal medicines may have different dosage forms, and a herbal medicines may have various conventional dosage forms to meet different types of therapeutically methods.
  • each of the herbal medicines prepared by the process of the present invention may be used in combination of one or more physiological acceptable excipients and/or auxiliaries to give formulations or compositions for various medical applications.
  • a composition or formulation of the present invention comprises an effective amount of one of the herbal medicines of the present invention and one or more physiological acceptable excipients and or auxiliaries.
  • the excipients and/or auxiliaries are conventional and known to the person skilled in the art.
  • Raw material which may be processed by using the present invention for preparing herbal medicines are all these raw materials which has been used as raw material for preparing herbal medicines in conventional methods.
  • animals such as insects, aquatic animals and terrestrial animals; plants such as terrestrial plants and aquatic plants; and minerals such as metal salts, metal oxides and nonmetal oxides; etc.
  • the herbal medicines can be in the preparation forms for oral, rectal parenteral, transdermal and topical administration.
  • Forms for oral administration include, for example, tablets, coated tablets, capsules, medicines to be taken after being mixed with boiling water, wine, etc. pellets, and powder and for rectal administration include suppositories.
  • Topical forms include solutions, lotions, creams, ointments, powders and other conventional forms for the application of the herbal medicines to the skin.
  • the herbal medicines is administrated by either intravenous or intramuscular injection.
  • a herbal medicine is prepared by the process of the present invention in which a multi-enzyme system is used to treat raw materials in order to transfer high moleculer materials into low moleculer materials.
  • Liquorice soft extract and liquorice polysaccharose are prepared from licorice roots. According to the present invention. Liquorice soft extract or liquorice polysaccharose is used for the inhibition and/or curing of diseases such as gastrointestinal disease and tumors. And they are also used for lowering the level of blood sugar, blood-lipid or serum cholesterol, increasing the rate of HDL (High Density Lipoprotein) and improving the functions of cardio-cerebral blood vessel.
  • HDL High Density Lipoprotein
  • the herbal medicine is administrated in the range of 2 to 20 mg per kilogram of body weight per day and the daily dose is divided into four individual doses.
  • the herbal medicine is administrated in the range of 0.1 to 0.5 mg per kilogram of body weight per day and the daily dose is divided into two individual doses.
  • Preparation of liquorice soft extract and liquorice polysaccharose from Licorice Root 100 Kg of licorice root was cracked to an average particle size of about 100 meshes. The particles were soaked for about 24 hours and were finely ground to a size of about 5 ⁇ m. 0.5 g enzymes were added which comprise 35% of cellulase, 12% of protease, 40% of amylase, 3% of lipase, 5% of lysozyme and 5% of glucase peptidase and have a specific activity concentration of 2 IU/g substrate. The enzyme treatment was done for about 5 hours. The material was filtered and the filtrate was concentrated to form liquorice soft extract. The yield of licorice acid is about 90 to 99%.
  • the residue of the filtration was added with water and finely ground to an average size of about 10 ⁇ m or below. 12g of the same enzymes were added to adjust the specific activity concentration to 50 IU/g substrate. The enzyme treatment was done at about 65° C. for about 10 hours. After the enzyme treatment, the material was second finely ground again and then filtered to remove the residue. The filtrate was concentrated at a low temperature of 45° C. and dried by spray to form liquorice polysaccharose (oligosaccharide) The product has solubility of 100%. The residue rate is about 1 to 3% (dry weight).
  • the liquorice polysaccharose produced according to the present Examples has inhibitive and curative effect to enterogastric diseases and oncoma.
  • the dose of oral administration is 200 ⁇ 2000 mg/day, it can effectively decrease the level of blood sugar, blood-lipid and blood cholesterol, increase the ratio of HDL (High Density Lipoprotein) and improve functions of cardio-cerebral blood vessels.
  • the herbal medicine may also effectively inhibit AIDS virus and inhence the immunological competence of patients.
  • a herbal medicine is prepared by the process of the present invention, which comprises 10 ⁇ 40% of mahonia stem, 10 ⁇ 40% of siegesbeckia herb, ⁇ 45% of speranskia tuberculate and 5 ⁇ 30% of cnidium fruit.
  • the herbal medicine is used for the treatment of rheumatism (AS/RS) such as rheumatic arthritis, rhemnatoid arthritis, hyperosteogeny, osteocutanneous inflammation, cervical vertabra disease, rheumatic heart disease, lupus erythematosus, cervical vertabra disease and cor pulmonale, etc.
  • AS/RS rheumatism
  • the herbal medicine is administrated in the range of 25 to 60 mg per kilogram of body weight per day the daily dose is divided into four individual doses.
  • the herbal medicine is administrated in the range of 2 to 4 mg per kilogram of body weight per day and the daily dose is divided into individual doses.
  • 10 Kg of mahonia stem, 20 Kg of siegesbeckia herb, 15 Kg of speranskia tuberculate and 5 Kg of cnidium fruit were mixed and cracked into particles with an average sizes of 600 meshes. The particles were soaked for 12 to 24 hours, and then were first finely ground to an average sizes of 10 ⁇ m or below.
  • 10 g of enzymes were added to treat, with a specific activity concentration of 125 IU/g substrate, the ground material with stirring at 50° C. for 72 hours.
  • the enzymes comprised 60% of cellulase, 15% of protease, 10% of amylase, 5% of lipase, 5% of lysozymes and 5% of peptichainase. After the enzyme treatment, the material was finely ground again.
  • the ground mash may either directly be formulated to pellets, capsules or tablets be formulated to ointment or lotion or bath solution for the applications to skin.
  • the ground mash after the enzyme treatment from Embodiment II-1 was filtered and the filtrate was then sterilized at a temperature of 50° C.
  • the residuce rate was 6 ⁇ 10%.
  • the material may be formulated for the applications of oral administration or topical administration.
  • I. Method of trandermal absorption take 8 ⁇ 20 g product of the herbal medicine, steeped in 50 ⁇ 100 ml of medical alcohol for 1 ⁇ 60 minutes or longer, add 20 ⁇ 50 liters of water at temperature lower than 45° C. to form a solution, let a patient be steeped in the solution for 20 ⁇ 60 minutes.
  • the temperature of water may either be kept or not be kept the same during the treatment.
  • the patient should be kept warm and stay away from cool blow after the steeping treatment.
  • the patient may moderately drink wine during the treatment, and is prohibited from eating raw, cold, fatty food, meat, fish and other food that are not fresh.
  • the effects of the treatment are as follows:
  • a. can effectively eliminate focus of connective tissue, make collagen tissue recover normal ability
  • b. can effectively decompose and through blood or body fluid circulation remove hyperosteogeny substance, and expel harmful substance from body;
  • c. can effectively recover impaired functions of motor nerve and autonomic nerve
  • the cure rate of rhematic arthritis, rheumatoid arthritis, hyperosteogeny, osteocutanneous inflammation, cervical vertabra disease, rheumatic heart disease and lupus erythematosus is above 90%, the effective rate is above 95%, the cure rate of rigor vertebra inflammation and cor pulmonale is above 70% and effective rate is above 85% (see Table 1).
  • the cure rate of rheumatic arthritis, rheumatoid arthritis, hyperosteogeny, osteocutanneous inflammation, cervical vertabra disease, rheumatic heart disease and lupus erythematosus is above 80%, effective rate is above 95%.
  • LD 50 on mise by intravenous injection is 1.0 g/kg (converted to dry powder), oral medication is 4.5 g/kg.
  • Aqueous solution (0.1%) outside the body can effectively inhibit staphylococcus aureus, colicine and pseudomonas aemginosa. Injecting 10% aqueous solution or alcholic solution in a dose of 0.01 g/kg into rat or white rabbit, will distinctly inhibit egg-white-like rheumatic arthritis.
  • a herbal medicine is prepared by the process of the present invention which comprises 10 to 35% of goldthread root, 10 to 35% of yellow-corktree bark, 5 to 50% of rhubarb, 5 to 40% of scutellaria root, 1 to 65% of pricklyash peel.
  • the herbal medicine is administrated for treating diseases such as bacterial dematosis, fungal dermatosis, infection of urinary system, hemorrhoid and sore, etc.
  • the herbal medicine is administrated in the range of 10 to 30 mg per kilogram body weight per day and the daily dose is divided into four individual doses.
  • the herbal medicine is administrated in the range of 0.5 to 3 mg per kilogram body weight per day and the daily dose is divided into two individual doses
  • LD 50 by oral taking on mise is 2.5 g/kg
  • LD 50 by injection is 1.8 g/kg
  • it has no sub and teratogenic toxicity.
  • the herbal medicine has a capacity of inhibiting the growth or destroying hemolytic streptococcus, meningococcus, pneumococcus, vibriocholera, bacillus anthracis, staphylococcus aureus, bacillus dysenteriae, corynebacterium diphtheria, hay bacillus, pestis, bacillus proteus, bacterium coli, typhoid bacillus, bacillus pyocyaneus, etc.
  • the mechanism is that it can inhibit the formation composition of DNA/RNA and protein of bacteria, strengthen the engulfing ability of white cell, T lymphocyte cell and liver reticuloendothelial system.
  • Blood Sugar/Blood-lipid It has no effect on ration of serum cholesterol/total phospholipid of normal people, and can lower abnormal ratio of serum cholesterol/total phospholipid;
  • Sedative Effect It can inhibit raises spontaneous activity and positive conditioned reflex, eliminate frog, cat and dog's tonic spasm symptom caused by strychnine poisoning, enable animal escape from death (orally taking 100 mg every day, can raise LD 50 by 2.5 times as much as previous.)
  • 100 Kg of goldthread root, 60 Kg of yellow-croktree bark, 50 Kg of rhubarb, 100 Kg of scutellaria root and 90 Kg of pricklyash peel were mixed and cracked into particles with an average size of 2000 meshes. The particles were soaked for 6 hours and then finely ground to an average sized of 2 ⁇ m or below. 40 g of enzymes were added to give a specific activity concentration of 800 IU/g substrate. The enzymes were composed of 36% of cellulase, 22% of protease, 32% of amylase, 1% of lipase and 9% of lysozyme. The enzyme treatment was made at 75° C. for 48 hours.
  • the mash was finely ground again.
  • the ground mash was then filtered.
  • the filtrate was sterilized in the same way as Embodiment I-1.
  • the sterilized mash may be formulated for different applications, such as, lotions, oniments or creams, etc. for madication of skin, and the sterilized mash may also be concentrated and dried to form a product which may be used in fomulations of tablets, capsules or bath formulation, etc.
  • a herbal medicine comprising 5 to 40% of flavescent sophora root, 10 to 55% of stemona root, 10 to 35% of cnidium fruit, 5 to 60% of portulaca, 10 to 40% of gentian root and 5 to 60% of goldthread root, is prepared by the process of the present invention.
  • the herbal medicine has application for treating various itches caused by, for example, skin dry, immunity endocrine uneguililium, or physical or chemical allergy. It can also inhibit itches caused by various tumors, psoriasis and neurodermatitis.
  • the deliver way may be transdermal absorption, oral or injection. It can be used to cure itch caused by dry, immunity endocrine umeguililium, or physical/chemical allergy.
  • the herbal medicine is administrated in the range of 10 to 30 mg per kilogram body weight per day and the daily dose is divided into four individual doses.
  • the herbal medicine is administrated in the range of 1 to 4 mg per kilogram body weight per day and the daily dose is divided into two individual doses.
  • LD 50 on mise by intravenous injection is 0.15 g/kg(converted to dry powder), oral medication is 0.9 g/kg.
  • the herbal medicine can inhibit the growth or destroy hemolytic streptococcus, emningococcus, pneumococcus, vibriocholera, bacillus anthracis, staphylococcus aureus, bacillus dysenteriae, corynebacterium diphtheria, hay bacillus, streptococcus viridans, pneumobacillus, bordetella pertussis, bacillus pestis, bruceliar, clostriddium tetani, bacillus perfringens, tubercle bacilli, bacillus, proteus, bacterium coli, typhoid bacillus, bacillus pyocyaneus, etc., the mechanism is that it can inhibit the formation of DNA/RNA and protein of bacteria, strengthen the engulfing ability of white cell, T lymphocyte cell and liver reticuloendothelial system.
  • Virus can inhibit XINCHENG virus, influenza virus and PR8, smallpox virus and rabies virus can enable chicken embryo cultured with XINCHENG virus to survive more than 20 hours. It can also inhibit various pollen viruses.
  • Clinical trials show that the herbal medicine can cur itches caused by various disease except itches caused by psoriasis and tumors.
  • the clinical trials were made by administrating the medicine on skin and the results are shown on Table 10.
  • the enzymes were composed of 30% of cellulase, 25% of protease, 25% of amylase, 10% of lipase, 2% of lysozyme, 4% of glucase peptidase and 4% of peptichainase.
  • the enzyme treatment was made with stirring at 30° C. for 90 hours.
  • the enzyme-treated mash was finely ground again.
  • the ground mash was filtered.
  • the residue rate was 1.4%.
  • the filtrate was then sterilized.
  • the sterilized mash may be formulated for medical applications to skin.
  • the mash may be concentrated and dried to give a product which may be used in preparation for oral or parenteral administration, such as, capsules, tablets and injections etc.
  • a herbal medicine comprising 10 to 70% of goldenlarch bark, 5 to 50% of goldthread root, 5 to 50% of flavescent sophora root, 5 to 60% of stemona root, 5 to 60% of white cloves, 5 to 40% of pricklyash peel, 5 to 70% of oldenlandia and 5 to 30% of portulaca is prepared by the process of the present invention.
  • the herbal medicine is administrated for treating diseases, for example, intractable itches such as, psoriasis, neurodermatitis, obstinate tinea, and viral itches such as, syphilis, gonorrhea and herpes zoster.
  • the herbal medicine is administrated in the range of 5 to 30 mg per kilogram body weight per day and the daily dose is divided into four individual doses.
  • the herbal medicine is administrated in the range of 0.5 to 5 mg per kilogram body weight per day and the daily dose is divided into two individual doses.
  • LD 50 by oral taking on mise is 1.2 g/kg
  • LD 50 by injection on mise is 0.2 g/kg
  • it has no sub and teratogenic toxicity.
  • the herbal medicine can inhibit the growth or destroy hemolytic streptococcus, meningococcus, pneumococcus, vibriocholera, bacillus anthracis, staphylococcus aureus, bacillus dysenteriae, corynebacterium diphtheria, hay bacillus, streptococcus viridans, pneumobacillus, bordetella pertussis, bacillus pestis, brucellar proteus, bacterium coli, typhoid bacillus, bacillus pyocyaneus, etc., the mechanism is that it can inhibit the formulation of DNA/RNA and protein of bacteria, strengthen the engulfing ability of white cell, T lymphocyte cell and liver reticuloendothelial system.
  • Fungus It can destroy various dermatomyces and also can kill leptospira;
  • Virus can inhibit XINCHENG virus, influenza virus and it can also effectively inhibit hepatitis virus, such as hepatitis A, B, C, etc. and specific virus, such as, herpes zoster and syphilis etc.
  • the enzymes were composed of 40% of cellulase, 25% of protease, 25% of amylase, 3% of lipase, 4% of lysozyme, 1% of glucase peplidase and 2% of peptichainase.
  • the enzyme treatment was made with stirring at 45° C. for 144 hours.
  • the enzyme-treated mash was freely ground again.
  • the ground mash was filtered and the filtrate was sterilized.
  • the residue rate was 3 ⁇ 7%.
  • the sterilized mash may be formulated to applications on skin, such as, tincture, creams or lotions etc., and the sterilized mash may be spray dried to give a product which may be used in formulations for oral administration or of bath solution.
  • a herbal medicine comprising 10 ⁇ 70% of poria, 1 ⁇ 30% of pinellia tuber, 5 ⁇ 50% of pilose asiabell root, 1 ⁇ 50% of immature bitter orange, 5 ⁇ 40% of green tangerine orange peel, 1 ⁇ 30% of atractylodes rhizome, 1 ⁇ 25% of fresh ginger, 5 ⁇ 40% of oldenlandia and 5 ⁇ 40% of lonicera japonica flower, is prepared by the process of the present invention.
  • the herbal medicine is used for treating diseases, such as, angina and pharyngitis, cardiatitis, esophagitis, enterogastritis, gastroenter ulcer, haemorrhoids, constipation, berhia, dyspepsia gastroenterli and gastroentercancer and other various tumor affections in the system, etc.
  • diseases such as, angina and pharyngitis, cardiatitis, esophagitis, enterogastritis, gastroenter ulcer, haemorrhoids, constipation, berhia, dyspepsia gastroenterli and gastroentercancer and other various tumor affections in the system, etc.
  • the herbal medicine is administrated in the range of 10 to 40 mg per kilogram body weight per day and the daily dose is divided into four individual doses.
  • the herbal medicine is administrated in the range of 1 to 5 mg per kilogram body weight per day and the daily dose is divided into two individual doses.
  • LD 50 by oral taking on mise is 50 g/kg, it has no up-limit and has no sub and teratogenic toxicity.
  • the herbal medicine can inhibit the growth or destroy hemolytic streptococcus, meningococcus, bacillus anthracis staphylococcus aureus, bacillus dysenteriae, bacterium coli, bacillus pyocyaneus, etc.,
  • the cure rate is higher than 85%, and effective rate is higher than 97%. It has a good inhibiting and curative effects on various tumor canceration of digestive system, such as, cardia cancer, laryngocarcinoma and gastroenteric cancer, etc..
  • the effective rate is higher than 80%.
  • the enzymes were composed of 20% of cellulase, 10% of protease, 37% of amylase, 11% of lipase, 10% of lysozyme, 4% of glucase peptidase and 8% of peptichainase.
  • the enzyme treatment was made with stirring at 75° C. for 72 hours.
  • the enzyme-treated mash was then finely ground again and was filtered.
  • the residue rate was 2.4%.
  • the filtrate was sterilized.
  • the sterilized mash may be formulated to give oral liquid
  • the sterilized mash may also be, after dried, prepared for various medical applications in formulations such as, pellets, capsules, tablets, powders or both formulations, etc.
  • a herbal medicine comprising 5 ⁇ 50% of Chinese yam, 5 ⁇ 65% of pueraria root, 10 ⁇ 70% of poria, 5 ⁇ 75% of dried rehmannia root, 5 ⁇ 60% of wolfberry fruit, 5 ⁇ 50% of pollen, 5 ⁇ 40% of rhizoma alismatis, 1 ⁇ 35% of mulberry leaf, 1 ⁇ 50% of lotus leaf, 1 ⁇ 50% of atractylodes rhizome, 0 ⁇ 35% of cherokee rose-hep and 5 ⁇ 65% of black plum is prepared by the process of the present invention.
  • the herbal medicine is used for treating diseases such as diabetes mellitus.
  • the herbal medicine is administrated in the range of 10 to 50 mg(for NIDDM patients: 10 to 30 mg, IDDM patients: 20 to 50 mg, Cancer patients: 40 to 50 mg) per kilogram body weight per day and the daily dose is divided into four individual doses.
  • the herbal medicine is administrated in the range of 1 to 10 mg(for NIDDM patients: 1 to 4 mg, IDDM patients: 3 to 10 mg, Cancer patients: 6 to 10 mg) per kilogram body weight per day and the daily dose is divided into two individual doses.
  • LD 50 by oral taking on mice is 12 g/kg
  • LD 50 by injection is 12 g/kg
  • Control group are fed with multivitamin pill (100 mg/per pill)
  • the herbal medicine can inhibit zymoexciting system (SH enzyme) of mastocyte.
  • the organization structure and physiological function of the pathological changed organs can be recovered to normal conditions.
  • patients can recover from glomeruli, renal pelvis, damages, nerves opticus damages and pancreas damages.
  • the cure effect rate is higher than 75% and effect rate reaches to 97%.
  • the patients who use the drugs such as Dibotin, Glucophage etc. with hormone agent can begin to decrease the dosage of the drugs in the proportion of 20% each 5 ⁇ 7 days from a week after they begin to use the herbal medicine of the present invention, and the patients will stop using the drugs in a month after they take the herbal medicine.
  • the patients who use the drugs such as D860, diabinese Glyburide, Diamicron, Glutril, Glurenorm etc., can begin to decrease 20% of the dosage of the drugs, in first 5 to 7 days after they take the herbal medicine of the present invention, and drop 20% each 5 days after first decrease (in practice, the proportional is according to the rehabilitation of the secretion level of insulin).
  • the dosage of insulin would be decreased 20% within first 5 ⁇ 7 days after the herbal medicine is taken and then decreased 20% each 5 ⁇ 10 days. And no insulin will be taken after 70 ⁇ 10 weeks.
  • the decreasing of the dosages may be according to the rehabilitation of the secretion of insulin of himself.
  • the enzymes were composed of 19% of cellulase, 22% of protease, 40% of amylase, 3% of lipase, 10% of lysozyme, 3% of glucase peptidase and 3% of peptichainase.
  • the enzyme treatment was made with stirring at 55° C. for 100 hours.
  • the enzyme-treated mash was finely ground again and filtered. The residue rate was 3%.
  • the filtrate was then sterilized.
  • the sterilized mash may be prepared to give oral solutions. After dried, the sterilized mash may be used in formulations, such as, pellets, tablets, eapsuals, powder or immersion formulations for administration to skin by immersion method etc.
  • a herbal medicine comprising 5 ⁇ 30% of oriental wormwood, 1 ⁇ 25% of red sage root, 1 ⁇ 30% of dandelion herb, 2 ⁇ 25% of bupleurum root, 1 ⁇ 20% of scutellaria root, 0 ⁇ 40% of oldenlandia, 0 ⁇ 35% of pollen, 0 ⁇ 30% of wolfberry fruit, 1 ⁇ 25% of mulberry leaf, 1 ⁇ 25% of rhizoma alismatis is prepared by the process of the present invention.
  • the herbal medicine is administrated in the range of 10 to 25 mg(for Cancer patients: 20 to 40 mg) per kilogram body weight per day and the daily dose is divided into four individual doses.
  • the herbal medicine is administrated in the range of 1 to 4 mg(for Cancer patients: 3 to 8 mg) per kilogram body weight per day and the daily dose is divided into two individual doses.
  • LD 50 on mise by intravenous injection is 2.5 g/kg(converted to powder), oral medication is 11.0 g/kg(dried powder).
  • the herbal medicine can inhibit the growth of hemolytic Streptococcus, Pneumococcus, Staphylococcus aureus, Bacillus dysentefiae, Corynebactefium diphtheria, Pneumobacillus, bovine or human tubercle Bacilli, etc.
  • Fungus and protozoon It can inhibit the growth of various dermatomyces and also can anaesthetize roundworm and earthworm.
  • Antipyretic Effect It has an antipyretic effect on febrile experimental animals (such as rabbits and dogs), but no effect on normal rabbit;
  • Diuretic Effect It can increase the urinary volume of domestic rabbits with toxic hepatitis and change the urea color from yellow to clear.
  • 20 Kg of oriental wormwood, 3 Kg of red sage root, 15 Kg of damdelion herb, 6 Kg of bupleurum root, 9 Kg of scutellaria root, 15 Kg of oldenlandia, 6 Kg of pollen, 6 Kg of wolfberry fruit, 8 Kg of mulberry leaf and 12 Kg of rhizoma alismatis were mixed and cracked into particles with an average size of 2000 meshes. The particles were soaked for 6 hours and finely ground to an average size of 2 ⁇ m or below. 6 g of enzymes were added to give a specific activity concentration of 8 IU/g substrate.
  • the enzymes were composed of 29% of cellulase, 10% of protease, 45% of amylase, 2% of lipase, 8% of lysozyme, 3% of glucase peptidase and 3% of peptichainase.
  • the enzyme treatment was made with stirring at 60° C. for 24 hours.
  • the enzyme-treated mash was finely ground again and filtered and ultra-filtered.
  • the residue rate was 2.2%.
  • the filtrate was concentrated under vacuum and spray dried. The product is used in formulations for various medical applications.
  • a herbal medicine comprising of 1 ⁇ 30% of tetrandra root, 1 ⁇ 20 % of ginseng, 5 ⁇ 40% of cinnamom twig, 5 ⁇ 30% of plaster stone, 5 ⁇ 30% of lotus leaf, 5 ⁇ 30% of mulberry leaf, 1 ⁇ 25% of immature bitter orange and 1 ⁇ 40% of Cherokee rose-hip is prepared by the process of the present invention.
  • the herbal medicine is administrated in the range of 5 to 10 mg per kilogram body weight per day and the daily dose is divided into four individual doses.
  • the herbal medicine is administrated in the range of 0.5 to 1 mg per kilogram body weight per day and the daily dose is divided into two individual doses.
  • the herbal medicine can reduce the permeability of blood vessels and decrease greatly the occurrence rate of serious shock sympton caused by holoalbumen and the death rate, have notable effect to Dutch pig histamine toxic shock; can also inhibit immune hemolysis, activate lymph node, increase weight and concentration of DNA/RNA in plasmablasts and plasmocytes, and increase the amount of such cells.
  • Effect to circulatory system It can be as hypotensor by intravenous injection, intramuscular injection or oral administration and the reduction of blood pressure can be 30 ⁇ 65% and last longer than 2 hours without notable changes to systole, heart rate and blood transmission; can also expand blood vessels, strengthen acetylcholine's reduction effect to blood pressure, and inhibit or relieve the blood pressure boost caused by repressing aorta.
  • Clinical practice proved that using product made by the present Embodiment to cure cardio-cerebral and blood vessel diseases, such as hypertension, hyperlipemia, coronary heart disease, arteriosclerosis etc., decrease cholesterol, triglyceride and low density lipoprotein in blood, raise the content of high density lipoprotein, adjust blood viscosity and soften blood vessels.
  • the effective rate is over 95%.
  • the enzymes were composed of 27% of cellulase, 24% of protease, 15% of amylase, 10% of pectase, 15% of hemicellulase, 4% of lysozyme, 3% of gulcase peptidase and 2% of peptichainase.
  • the enzyment treatment was carried on with stirring at 50° C. for 24 hours.
  • the enzyme-treated mash was finely ground again and filtered and ultrafiltered. The residue rate was 3%.
  • the filtered mash was then sterilized and was then treated by an ultrasonic method and was then concentrated and dried to give a product.
  • the product is to be used in formulations for various medical applications.
  • a herbal medicine comprising 5 ⁇ 30% of ginseng, 5 ⁇ 30 % of astragahis root, 5 ⁇ 40% of lotus leaf, 5 ⁇ 35% of schizonepeta and 5 ⁇ 25% of tetrandra root is prepared by the process of the present invention.
  • the herbal medicine is administration in the range of 10 to 30 mg per kilogram body weight per day and the daily dose is divided into four individual doses.
  • the herbal medicine is administration in the range of 1 to 2 mg per kilogram body weight per day and the daily dose is divided into two individual doses.
  • 10 Kg of ginseng, 10 Kg of lotus leaf, 10 Kg of schizonepeta and 10 Kg of tetrandra root were mixed and cracked into a particles with an average size of about 1200 meshes. The particles were soaked for 5 hours and finely ground to give a mash with an average partical size of 10 ⁇ m or below. 2 g of enzymes were added to give a specific activity concentration of 16 IU/g. The enzymes were composed of 10% of cellulase, 35% of protease, 15% of amylase, 10% of pectase, 15% of hemicellulase, 10% of lysozyme and 5% of glucase peptidase.
  • the enzyme-treatment was made with stirring at 70° C. for 24 hours.
  • the enzyme-treated mash was finely ground again, filtered and ultrafitered.
  • the residue rate was about 2%.
  • the filtered mash was then treated by an ultrasonic method, concentrated and dried to give a product.
  • the product may be used in formulations for various medical applications.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This invention relates to a process for preparing a herbal medicine by using a multi-enzyme to hydrolyze raw materials. The multi-enzyme system comprises cellulases, proteases, amylases, lipases and lysozyme, and may further comprise a supplementary enzyme, and a herbal medicine prepared by the process of the invention.

Description

This invention relates to a process of preparing herbal medicines by using a multi-enzyme system and relates to herbal medicines made by the process and their pharmaceutical uses.
BACKGROUND OF THE INVENTION
Herbal medicines have been used for treating various diseases in various countries for a very long period of time. The preparations of herbal medicines have been developed in years. A typical traditional method for example, used in China is a physical preparation method, such as, stirring-baking, decocting and parching.
In recent decades, a chemical purification method has been developed for preparing herbal medicines in which active ingredients of raw material are extracted and purified. Without the balance of other ingredients, the toxicity and side effects are increased in the herbal medicines prepared by the chemical purification method.
A new method of preparing herbal medicines is desired by which herbal medicines have quicker therapeutical effect and lower toxicity and side effects.
SUMMARY OF THE INVENTION
One of the objections of the present invention is to provide a process for preparing herbal medicines in which a multi-enzyme system is used in treating raw materials.
Another objection of the present invention is to provide new herbal medicines prepared by using a multi-enzyme system which may be used in treating various diseases.
Another objection of the present invention is to provide new herbal medicines which have better solubility and higher therapeutical effect.
Another objection of the present invention is to provide a process for preparing herbal medicine at lower costs in which a multi-enzyme system is employed to increase the solubility of the herbal medicines by transferring large molecular materials into low molecular materials.
Further and other objections of the present invention may be illustrated from the following description of the present invention in detail.
According to the present invention, a process of preparing a herbal medicine comprises the steps of forming a mash from raw material, first finely grinding the mash so that the size of the suspension particles of the said mash is less than 50 μm, treating the ground material with biological enzymes to promote the hydrolysis of the said material in which the biological enzymes form a multi-enzyme system comprising cellulases, proteases, amylases, lipases and lysozymes, and sterilizing the enzymatic hydrolysis material.
The present invention relates also to the herbal medicines prepared by the above mentioned process and uses of these herbal medicines in the treatment of human and/or animal diseases.
There are many advantages as follows by using multi-enzyme system to process herbal medicines preparations.
1. The solubility of original medicines can be dramatically improved and increased from 4-5% in traditional method to 65-99%;
2. The ratio of dissolution of effective medical composition of original medicine can greatly be increased due to the reinforcing treatment of solubility. It can be increased to nearly 100%, which facilitates processing and purification.
3. That high molecular materials, such as cellulose, protein, starch etc. can be conversed into oligosaccharide, oligopepitde, and saponin which can be very easily absorbed by human body, leads to inductive absorption. As a result, the absorptivity of effective medical compositions can be increased to nearly 100% from 10-60% of traditional method. The therapeutical effect is prominent and the effectual time is greatly shortened to be the same as that of western medicines.
4. Oligosaccharide, oligopeptide and saponin have effects in regulating human body's immunity and endocrine functions and can be used for immunity therapy in modem medicines. Therefore, a number of oligosaccharides and oligopeptides, existing in the Chinese herbal medicine preparations by the process of the present invention, can reinforce the effect, so that the effective dosages of Chinese herbal medicines may be reduced to 1/10- 1/200 of that in the traditional method.
5. During the process of production, conventional techniques in high temperature treatment, such as stirring-baking, parching and decocting have been totally discarded. The processing is carried out under mild condition with normal temperature, which avoids color deteriorated change on account of oxidation and etc., and makes preparations mainly keep the color of original medicines. In addition, the outward appearance of products can be accepted easily.
6. It is the present invention that makes the form of Chinese herbal medicine wonderful, such as, small dosage, good quality and fine processing, without boorish outward appearance.
7. The process of the present invention has no selectivity to raw materials, which adapts to any medicines from animal and plant resources.
8. The medicines prepared by the process of the present invention, being rich in bio-active materials, can effectively promote the reparation of ribose nucleic acids (RNA) and deoxyribonucleic acids (DNA). That is, enzymes secreted from cells can decompose diseased ribose nucleic acids and deoxyribonucleic acids, at the same time, can promote the synthesis of normal ribose nucleic acids and deoxyribonucleic acid and facilitate the synthetic speed (it is about 2-5 times faster than that under usual conditions). Neogenesic cells can clear the foci as well as repair the structure and function of diseased tissues. In such a way, they can provide effective therapy to those diseases, which can not be cured by traditional Chinese and western medicines, such as diabetes mellitus, hyperosteogeny, oncosis, rheumatic/rheumatoid arthritis, diseased connective tissue and collagen, psoriasis etc. At the same time, the herbal medicines of the present invention have a function of systematic therapy. That is to say that one particular herbal medicine can be used for treating all diseases in a particular anatomical system.
9. When the medicines prepared by the process are used in therapy, its methods of medical caring completely follow the theories of modem molecular medicine and cell medicine. It is scientifically and practically better than traditional ways, and can greatly increase the curative rate.
DETAILED DESCRIPTION OF INVENTION
According to the present invention, a process of preparing herbal medicines comprises treating a raw material with biological enzyme system that contains multi-biological enzymes to promote the hydrolysis of the said raw material. Before treated with the multi-enzyme system, the raw material is pre-treated in the following steps.
First, the raw material is crushed or beaten to form a mash by conventional processes, such as mechanical crushing or beating process. The particles of the crushed or beaten raw material are small, making it easier to perform the next steps. The average size of the said particles is about 600 meshes to about 2000 meshes. During the formation of the mash, the crushed or beaten raw material may also be soaked. In some instances, the soaked step may be taken place before the raw material is crushed or beaten, particularly when the raw material is drier. Generally speaking, moisture in the raw material is gradually lost during storing, and the longer the material is stored, the more moisture will be lost. Therefore, when raw material has less than 50% of moisture/content, an adequate amount of water is added during the step of soaking in order to maintain the moisture content of the cracked raw material higher than 50%, preferably between 75% to 80%. The time of soaking varies according to the degree of freshness of the raw material. The fresher the material is, the shorter it will be pre-soaked. Normally, the soaking time is 15 minutes to 36 hours.
The soaked material is then subject to first fine grinding. The size of the suspended particles of the finely ground material is less than 50μm.
The ground mash is then treated with biological enzyme to promote the hydrolysis of the material while stirred. The biological enzyme used in the present invention is multi-enzyme system that comprises cellulases, proteases, amylases, lipases and lysozymes. In addition, according to the type of raw materials to be treated the multi-enzyme system may further comprises one or more of supplementary enzymes, such as hemicellulases, pectases, glucase peptidases, or peptichainases etc.
During the enzyme treatment, the activity. unit of the enzyme used is 20,000-10,000,000 IU/g and the specific activity concentration is about 1 to 1000 IU/g substrate. With the increase in the loss of moisture in the raw material, the specific activity concentration of the enzyme system used is slightly increase. Generally, the temperature of enzyme hydrolysis is about 20°-80° C. and the time of enzyme hydrolysis is from about 5 minutes to about 144 hours.
The enzyme-treated material may be subject to second finely grinding to give an average particle size of less than 5 μm in some cases.
After the second finely grinding, the enzyme-treated material may or may not be filtered to eliminate the residues which depends on the desired form of a herbal medicine produced. During the filtering step, the material is filtered so that the particles of the filtered material are of the desired average sizes.
In order to enable the product to have good stability and maintain maximum biologically active material, the enzyme-treated material, filtered or not filtered, is then sterilized. The sterilization of the present invention is carried out under a temperature about 50° C. or below.
The sterilizing step in the present invention involves using ultrafiltration or ultrasonic sterilizing method. Or both ultrofiltration and ultrasonic method are used. The ultrasonic sterilizing method comprises killing the bacterium and enzyme and sterilizing the material while it is flowing through an ultrasonication apparatus. The frequency of the ultrasonic waves suitable for use in the present invention is about 20-100 KHz, the power density is over 100 W/cm2, and the flow speed is about 1-25 m/s.
According to the present invention, the multi-enzyme system used in the process comprises, by weight, 5-75% of cellulases, 5 to 50% of proteases, 5 to 50% of amylases, 1 to 20% of lipases, and 1 to 15% of lysozymes. Depending on the raw materials to be processed, the multi-enzyme system may further comprise one or more supplementary enzymes, for example, 0 to 15% of hemicellulases, 0 to 30% of pectases; 0 to 10% glucase peptidases; and 0 to 10% of peptichainases.
After the sterilization step, the sterilization material may be adjusted to a suitable form for preparing a desired dosage form of a herbal medicine by conventional means such as, concentration in vacuum, and spray drying etc.
The desired dosage forms depend on the herbal medicines which are produced. Different herbal medicines may have different dosage forms, and a herbal medicines may have various conventional dosage forms to meet different types of therapeutically methods.
According to the present t invention, each of the herbal medicines prepared by the process of the present invention may be used in combination of one or more physiological acceptable excipients and/or auxiliaries to give formulations or compositions for various medical applications. A composition or formulation of the present invention comprises an effective amount of one of the herbal medicines of the present invention and one or more physiological acceptable excipients and or auxiliaries. The excipients and/or auxiliaries are conventional and known to the person skilled in the art.
Raw material which may be processed by using the present invention for preparing herbal medicines, are all these raw materials which has been used as raw material for preparing herbal medicines in conventional methods. For example, animals such as insects, aquatic animals and terrestrial animals; plants such as terrestrial plants and aquatic plants; and minerals such as metal salts, metal oxides and nonmetal oxides; etc.
The following examples will further illustrate the present invention and all the percentages used in the text are on the basis of weight unless otherwise indicated.
The herbal medicines can be in the preparation forms for oral, rectal parenteral, transdermal and topical administration. Forms for oral administration include, for example, tablets, coated tablets, capsules, medicines to be taken after being mixed with boiling water, wine, etc. pellets, and powder and for rectal administration include suppositories.
Topical forms include solutions, lotions, creams, ointments, powders and other conventional forms for the application of the herbal medicines to the skin.
For parenteral administration, the herbal medicines is administrated by either intravenous or intramuscular injection.
According to the present invention, a herbal medicine is prepared by the process of the present invention in which a multi-enzyme system is used to treat raw materials in order to transfer high moleculer materials into low moleculer materials.
By using the process of the present invention. Liquorice soft extract and liquorice polysaccharose are prepared from licorice roots. According to the present invention. Liquorice soft extract or liquorice polysaccharose is used for the inhibition and/or curing of diseases such as gastrointestinal disease and tumors. And they are also used for lowering the level of blood sugar, blood-lipid or serum cholesterol, increasing the rate of HDL (High Density Lipoprotein) and improving the functions of cardio-cerebral blood vessel.
For oral administration, the herbal medicine is administrated in the range of 2 to 20 mg per kilogram of body weight per day and the daily dose is divided into four individual doses.
For injection administration, the herbal medicine is administrated in the range of 0.1 to 0.5 mg per kilogram of body weight per day and the daily dose is divided into two individual doses.
Embodiment I
Preparation of liquorice soft extract and liquorice polysaccharose from Licorice Root. 100 Kg of licorice root was cracked to an average particle size of about 100 meshes. The particles were soaked for about 24 hours and were finely ground to a size of about 5 μm. 0.5 g enzymes were added which comprise 35% of cellulase, 12% of protease, 40% of amylase, 3% of lipase, 5% of lysozyme and 5% of glucase peptidase and have a specific activity concentration of 2 IU/g substrate. The enzyme treatment was done for about 5 hours. The material was filtered and the filtrate was concentrated to form liquorice soft extract. The yield of licorice acid is about 90 to 99%. The residue of the filtration was added with water and finely ground to an average size of about 10 μm or below. 12g of the same enzymes were added to adjust the specific activity concentration to 50 IU/g substrate. The enzyme treatment was done at about 65° C. for about 10 hours. After the enzyme treatment, the material was second finely ground again and then filtered to remove the residue. The filtrate was concentrated at a low temperature of 45° C. and dried by spray to form liquorice polysaccharose (oligosaccharide) The product has solubility of 100%. The residue rate is about 1 to 3% (dry weight).
Clinical practice proved that the liquorice polysaccharose produced according to the present Examples has inhibitive and curative effect to enterogastric diseases and oncoma. When the dose of oral administration is 200˜2000 mg/day, it can effectively decrease the level of blood sugar, blood-lipid and blood cholesterol, increase the ratio of HDL (High Density Lipoprotein) and improve functions of cardio-cerebral blood vessels. The herbal medicine may also effectively inhibit AIDS virus and inhence the immunological competence of patients.
According to the present invention, a herbal medicine is prepared by the process of the present invention, which comprises 10˜40% of mahonia stem, 10˜40% of siegesbeckia herb, ˜45% of speranskia tuberculate and 5˜30% of cnidium fruit. The herbal medicine is used for the treatment of rheumatism (AS/RS) such as rheumatic arthritis, rhemnatoid arthritis, hyperosteogeny, osteocutanneous inflammation, cervical vertabra disease, rheumatic heart disease, lupus erythematosus, cervical vertabra disease and cor pulmonale, etc.
For oral administration, the herbal medicine is administrated in the range of 25 to 60 mg per kilogram of body weight per day the daily dose is divided into four individual doses.
For injection administration, the herbal medicine is administrated in the range of 2 to 4 mg per kilogram of body weight per day and the daily dose is divided into individual doses.
Embodiment II-1
10 Kg of mahonia stem, 20 Kg of siegesbeckia herb, 15 Kg of speranskia tuberculate and 5 Kg of cnidium fruit were mixed and cracked into particles with an average sizes of 600 meshes. The particles were soaked for 12 to 24 hours, and then were first finely ground to an average sizes of 10 μm or below. 10 g of enzymes were added to treat, with a specific activity concentration of 125 IU/g substrate, the ground material with stirring at 50° C. for 72 hours. The enzymes comprised 60% of cellulase, 15% of protease, 10% of amylase, 5% of lipase, 5% of lysozymes and 5% of peptichainase. After the enzyme treatment, the material was finely ground again. The ground mash may either directly be formulated to pellets, capsules or tablets be formulated to ointment or lotion or bath solution for the applications to skin.
Embodiment II-2
The ground mash after the enzyme treatment from Embodiment II-1 was filtered and the filtrate was then sterilized at a temperature of 50° C. The residuce rate was 6˜10%. After the sterilization, the material may be formulated for the applications of oral administration or topical administration.
Embodiment II-3
10 Kg of mahonia stem, 10 Kg of siegesbeckia, 21 Kg of speranskia tuberculate and 9 Kg of cnidium fruit were mixed and cracked into particles with an average size of 1000 meshes. The soaking and finely grinding steps were the same as the Embodiment II-1. 6 g of enzymes were added to give a specific activity concentration of 75 IU/g substrate. The enzymes were composed of 44% of cellulase, 18% of protease, 18% of amylase, 10% of lipase, 5% of lysozyme and 5% of peptichainase. The enzyme treatment was made with stirring at 30° C. for 48 hours. The material was then finely ground again. The ground mash was filtered and sterilized as the Embodiment II-2. The rate of the residue was 16%. After the sterilization the mash was concentrated and dried to form powder. The powder may be used in formulations for desired applications.
I. Method of trandermal absorption: take 8˜20 g product of the herbal medicine, steeped in 50˜100 ml of medical alcohol for 1˜60 minutes or longer, add 20˜50 liters of water at temperature lower than 45° C. to form a solution, let a patient be steeped in the solution for 20˜60 minutes. The temperature of water may either be kept or not be kept the same during the treatment. The patient should be kept warm and stay away from cool blow after the steeping treatment. The patient may moderately drink wine during the treatment, and is prohibited from eating raw, cold, fatty food, meat, fish and other food that are not fresh. The effects of the treatment are as follows:
a. can effectively eliminate focus of connective tissue, make collagen tissue recover normal ability;
b. can effectively decompose and through blood or body fluid circulation remove hyperosteogeny substance, and expel harmful substance from body;
c. can effectively recover impaired functions of motor nerve and autonomic nerve;
d. the cure rate of rhematic arthritis, rheumatoid arthritis, hyperosteogeny, osteocutanneous inflammation, cervical vertabra disease, rheumatic heart disease and lupus erythematosus is above 90%, the effective rate is above 95%, the cure rate of rigor vertebra inflammation and cor pulmonale is above 70% and effective rate is above 85% (see Table 1).
                                  TABLE 1                                 
__________________________________________________________________________
Summary of curative effect of clinical test human body-Method of          
transdermal absorption                                                    
                           Curative                                       
                           effect                                         
            Dosage                                                        
                 Duration  Effective                                      
                                Rate of                                   
Group    cases                                                            
            (g./day)                                                      
                 (day)                                                    
                      Cure rate                                           
                           rate no effect                                 
__________________________________________________________________________
Rheumatic                                                                 
         1858                                                             
            15 g 30   92.4%                                               
                           97.2%                                          
                                2.8%                                      
arthritis                                                                 
Rheumatoid                                                                
         99 15 g 3 × 30                                             
                      94.8%                                               
                           97.0%                                          
                                3.0%                                      
arthritis                                                                 
Hyperosteogeny                                                            
         146                                                              
            15 g 3 × 30                                             
                      91.8%                                               
                           95.9%                                          
                                4.1%                                      
Osteocutanneous                                                           
         147                                                              
            15 g 30   95.2%                                               
                           98.6%                                          
                                1.4%                                      
inflammation                                                              
Cervical vertebra                                                         
         189                                                              
            15 g 3 × 30                                             
                      90.5%                                               
                           92.6%                                          
                                7.4%                                      
disease                                                                   
Rheumatic hear                                                            
         44 15 g 30   97.7%                                               
                           100% 0%                                        
disease                                                                   
Lupus    47 15 g 3 × 30                                             
                      91.5%                                               
                           95.7%                                          
                                4.3%                                      
erythematosus                                                             
Rigor vertebra                                                            
         113                                                              
            2 × 15 g                                                
                 6 × 30                                             
                      71.4%                                               
                           87.4%                                          
                                12.6%                                     
inflammation                                                              
Cor pulmonale                                                             
         38 2 × 15 g                                                
                 6 × 30                                             
                      71.0%                                               
                           94.7%                                          
                                5.3%                                      
__________________________________________________________________________
II. Method of oral medication: Each time take capsul, powder or oral liquid, containing 400˜800 mg product of the herbal medicine, 4 times each day (about 30 minutes before breakfast, about 30 minutes before lunch, about 30 minutes before dinner and before sleep), take the medicine with warm water at temperature lower than 45° C. Keeping warm and stay away from cool blow after the treatment. Can moderately drink wine, prohibited form eating raw, cold, fatty food, meat, fish and other food that are not fresh during the treatment. The effects of the treatment are as follows:
a. the cure rate of rheumatic arthritis, rheumatoid arthritis, hyperosteogeny, osteocutanneous inflammation, cervical vertabra disease, rheumatic heart disease and lupus erythematosus is above 80%, effective rate is above 95%.
b. the cure rate of rigor vertebra inflammation and cor pulmonale is above 60% and effective rate is above 80% (see Table 2).
                                  TABLE 2                                 
__________________________________________________________________________
Summary of curative effects of clinical tests on human body orally.       
                                 Curative                                 
             Dosage                                                       
                  Number         effect                                   
             (mg./per                                                     
                  of times                                                
                       Duration  Effective                                
                                      Rate of                             
Group    Cases                                                            
             time (day)                                                   
                       (day)                                              
                            Cure rate                                     
                                 rate no effect                           
__________________________________________________________________________
Rheumatic                                                                 
         253 400  4    30   96.4%                                         
                                 100% 0%                                  
arthritis                                                                 
Rheumatoid                                                                
         443 400  4    3 × 30                                       
                            92.3%                                         
                                 95.5%                                    
                                      4.5%                                
arthritis                                                                 
Hyperosteogeny                                                            
         387 400  4    3 × 30                                       
                            82.5%                                         
                                 95.4%                                    
                                      4.6%                                
Osteocutanneous                                                           
         564 400  4    30   97.6%                                         
                                 100% 0%                                  
inflammation                                                              
Rigor vertebra                                                            
         221 400  4    3 × 30                                       
                            80.1%                                         
                                 96.4%                                    
                                      3.6%                                
inflammation                                                              
Rheumatic heart                                                           
         37  400  4    30   99.3%                                         
                                 100% 0%                                  
disease                                                                   
Lupus    61  600  4    3 × 30                                       
                            91.8%                                         
                                 100% 0%                                  
erythematosus                                                             
Rigor Vertebra                                                            
         187 600  4    6 × 30                                       
                            60.4%                                         
                                 98.4%                                    
                                      1.6%                                
inflammation                                                              
Cor pulmonale                                                             
         97  600  4    6 × 30                                       
                            65.0%                                         
                                 97.9%                                    
                                      2.1%                                
__________________________________________________________________________
Besides, using methods of applying on skin and so on are also having some effects, but there is no cure rate.
Combining methods of transdermal absorption, oral medication and applying on skin for treatment will enhance the cure effects.
Toxicity:
a. acute toxicity: LD50 on mise by intravenous injection is 1.0 g/kg (converted to dry powder), oral medication is 4.5 g/kg.
b. subacute toxicity: experimental result on rabbit (500±100 g) proved that there was no toxic symptom when 20 mg/kg of the drug delivered to the rectum of rabbit.
                                  TABLE 3                                 
__________________________________________________________________________
Experimental results of feeding animals                                   
     The amount                                                           
            Way of                                                        
                 Dosage                                                   
                      Duration    Result                                  
Group                                                                     
     of animal                                                            
            deliver                                                       
                 (mg/kg)                                                  
                      (day)                                               
                           Weight                                         
                               Diet                                       
                                  activity                                
                                      Defecating                          
                                            Death                         
__________________________________________________________________________
Watch                                                                     
     30     Rectum                                                        
                 20   7    ↑                                        
                               ↑                                    
                                  ↑                                 
                                      --    0                             
Control                                                                   
     10     Rectum                                                        
                 1 pill                                                   
                      7    ↑                                        
                               -- --  --    0                             
__________________________________________________________________________
 Note: (a) Control group are fed with multivitamin b pill (100 mg/per pill
 (b) "↑" stands for increase, "--" stands for normal                
 c. Teratogenicity: feeding experiment on mise for 6 months, does not show
 toxic teratogeny symptom.
Pharmacology:
1. Antiinflammation and Bacteriostasis Aqueous solution (0.1%) outside the body can effectively inhibit staphylococcus aureus, colicine and pseudomonas aemginosa. Injecting 10% aqueous solution or alcholic solution in a dose of 0.01 g/kg into rat or white rabbit, will distinctly inhibit egg-white-like rheumatic arthritis.
2. Alkaloids Reaction Low concentration (0.0001˜0.1%) will stimulate frog's heart separated from body, high concentration (>0.4%) has a little effect of inhibition; but has no effect on sciatic nerve-calf specimen, body temperature and blood sugar;
3. has an effect to inhibit the function of raising pressure of adrenalin, has a little effect for lowering blood pressure, but the effect is not related to central nerve.
4. has an antiviral effect on the XINCHENG virus, can effectively extend survival time of chicken embryo.
5. has an anti-cancer effect on ascites carcinoma and osteocarcinoma, but no haemocylolysis.
6. has a capacity to decompose spur and tuberculosis of bones and joints, make periosteal collagen tissue recover normal ability.
According to the present invention, a herbal medicine is prepared by the process of the present invention which comprises 10 to 35% of goldthread root, 10 to 35% of yellow-corktree bark, 5 to 50% of rhubarb, 5 to 40% of scutellaria root, 1 to 65% of pricklyash peel. The herbal medicine is administrated for treating diseases such as bacterial dematosis, fungal dermatosis, infection of urinary system, hemorrhoid and sore, etc.
For oral administration, the herbal medicine is administrated in the range of 10 to 30 mg per kilogram body weight per day and the daily dose is divided into four individual doses.
For injection administration, the herbal medicine is administrated in the range of 0.5 to 3 mg per kilogram body weight per day and the daily dose is divided into two individual doses
Toxicity:
LD50 by oral taking on mise is 2.5 g/kg, LD50 by injection is 1.8 g/kg, and it has no sub and teratogenic toxicity.
                                  TABLE 4                                 
__________________________________________________________________________
Experimental results from feeding animals                                 
     The amount                                                           
            Way of                                                        
                 Dosage                                                   
                      Duration    Result                                  
Group                                                                     
     of animal                                                            
            deliver                                                       
                 (mg/kg)                                                  
                      (day)                                               
                           Weight                                         
                               Diet                                       
                                  activity                                
                                      Defecating                          
                                            Death                         
__________________________________________________________________________
Watch                                                                     
     30     Rectum                                                        
                 100  7    ↑                                        
                               ↑                                    
                                  --  --    0                             
Control                                                                   
     10     Rectum                                                        
                 1 pill                                                   
                      7    ↑                                        
                               -- --  --    0                             
__________________________________________________________________________
 Note: (a) Control group are fed with multivitamin b pill (100 mg/per pill
 (b) "↑" stands for increase, "--" stands for normal, "↓"    
 stands for decent                                                        

                                  TABLE 5                                 
__________________________________________________________________________
Experimental results from injection in animals                            
     The amount                                                           
            Way of                                                        
                Dosage                                                    
                     Duration    Result                                   
Group                                                                     
     of animal                                                            
            deliver                                                       
                (mg/kg)                                                   
                     (day)                                                
                          Weight                                          
                              Diet                                        
                                 activity                                 
                                     Defecating                           
                                           Death                          
__________________________________________________________________________
Watch                                                                     
     30     Vein                                                          
                20   7    ↑                                         
                              -- --  --    0                              
Control                                                                   
     10     Vein                                                          
                1 tube                                                    
                     7    ↑                                         
                              -- --  --    0                              
                (2 ml)                                                    
__________________________________________________________________________
 Note (a) Injection water is used for control group                       
 (b) "↑" stands for increase, "--" stands for normal, "↓"    
 stands for decent
Pharmacology:
1. Effects of antimicrobial and antiprotozoon
(a) Bacteria The herbal medicine has a capacity of inhibiting the growth or destroying hemolytic streptococcus, meningococcus, pneumococcus, vibriocholera, bacillus anthracis, staphylococcus aureus, bacillus dysenteriae, corynebacterium diphtheria, hay bacillus, pestis, bacillus proteus, bacterium coli, typhoid bacillus, bacillus pyocyaneus, etc. The mechanism is that it can inhibit the formation composition of DNA/RNA and protein of bacteria, strengthen the engulfing ability of white cell, T lymphocyte cell and liver reticuloendothelial system.
(b) Fungus It has a capacity of destroying various dermatomyces and also can kill leptospira;
(c) Protozoon It has a capacity of inhibiting and destroying ameba protozoon trichomonad, leishmania donovani, trypanosome, paramecium etc.;
(d) Virus It can inhibit XINCHENG virus, influenza virus and PRS, can enable chicken embryo cultured with XINCHENG virus to survive more than 24 hours.
2. Anti-inflammation and anti allergic reaction
(a) It can impair zymoexciting system (SH enzyme) of mastocyte, inhibit release of anaphylactic, have an effect of remitting the hypersensitive contraction/asthma of extracorporeal/in vivo trachea and can inhibit passive cutaneous anaphylaxis and histamine reaction;
(b) It can inhibits hypersensitive inflammation and edema, lower permeability of capillary, prevent raise form bleeding reaction caused by low atmospheric pressure
3. Antipyretic Effect It has an effect on febrile rabbit caused by physical or chemical method, but no effect on normal rabbit;
4. Effect of lowering Blood Pressure and Diuretin It has a capacity of lowering blood pressure via dilatation of blood vessel, increasing volume of blood flow, at same time speeding the excretion of urinary system;
5. Blood Sugar/Blood-lipid It has no effect on ration of serum cholesterol/total phospholipid of normal people, and can lower abnormal ratio of serum cholesterol/total phospholipid;
6. Cholagogic Effect and the Effect of Spasmolysis It can increase the volume of biliation of dog and rabbit, has a conspicuous effect of inhibiting intestinal canal, and not relating to vagus nerve;
7. Sedative Effect It can inhibit raises spontaneous activity and positive conditioned reflex, eliminate frog, cat and dog's tonic spasm symptom caused by strychnine poisoning, enable animal escape from death (orally taking 100 mg every day, can raise LD50 by 2.5 times as much as previous.)
8. Effect of Anticancer, Antiradiation and Cellular Metabolism It can inhibit the formation of DNA/RNA of cancer cell, inhibit the growth of various tumors, have a direct destroying effect on mise's sarcoma, melanoma, mastadenoma and ascites carcinoma cell.
Clinical practice proved that the herbal medicine fro oral, injection or transdermal administration has an obvious curative effects on bacterial and fungal dermatosis, mosquito bite, poisonous bee and tussokmoth bite and various hypersensitive dermatosis caused by photosensitization, chemical and physical. Moreover it has a curative effect on hepatocarcinoma, digestive system tumor, endocrine system tumor and urinary system tumor.
                                  TABLE 6                                 
__________________________________________________________________________
Results form transdermal absorption treatment to bacterial dermatosis-    
immersion method                                                          
                              Curative                                    
            Dosage                                                        
                Number        effect                                      
       Cases                                                              
            (g/per                                                        
                of times                                                  
                     Duration                                             
                          Cure                                            
                              Effective                                   
                                   Rate of                                
Group  (person)                                                           
            time)                                                         
                (day)                                                     
                     (day)                                                
                          rate                                            
                              rate no effect                              
__________________________________________________________________________
Eczema 570  15  1    7    97.4%                                           
                              100% 0                                      
Pustule                                                                   
       60   15  1    7    100%                                            
                              100% 0                                      
and                                                                       
running                                                                   
sor                                                                       
Headsore                                                                  
       39   15  1    7    87.2%                                           
                              97.4%                                       
                                   2.6%                                   
Acne   105  15  1    7    84.8%                                           
                              100% 0                                      
Bedsore                                                                   
       74   15  1    7    83.8%                                           
                              100% 0                                      
Flatwart                                                                  
       43   15  1    7    72.1%                                           
                              97.7%                                       
                                   2.4%                                   
Sharp  47   15  1    2 × 7                                          
                          95.7%                                           
                              100% 0                                      
rheumatic                                                                 
wart                                                                      
Milliary                                                                  
       47   15  1    7    100%                                            
                              100% 0                                      
vesicle                                                                   
carbuncle                                                                 
       32   15  2    4 × 7                                          
                          90.6%                                           
                              100% 0                                      
Beriberi                                                                  
       192  15  1    4 × 7                                          
                          90.6%                                           
                              100% 0                                      
Plica  69   15  1    7    0   40.6%                                       
                                   59.4%                                  
Macula 62   15  1    7    100%                                            
                              100% 0                                      
Urticaria                                                                 
       71   15  1    7    100%                                            
                              1005 0                                      
Pudendaitch                                                               
       204  15  1    7    92.6%                                           
                              100% 0                                      
Skin   87   15  1    7    100%                                            
                              100% 0                                      
ulcer                                                                     
Gonorrhea                                                                 
       2    15  2    2 × 7                                          
                          100%                                            
                              100% 0                                      
__________________________________________________________________________

                                  TABLE 7                                 
__________________________________________________________________________
Results form transdermal absorption treatment to bacterial dermatosis-    
method of applying on skin                                                
                                  Curative                                
                  Number          effect                                  
            Dosage                                                        
                  of time                                                 
                        Duration                                          
                             Curative                                     
                                  Effective                               
                                       Rate of                            
Group   Cases                                                             
            (mg/time)                                                     
                  (time/day)                                              
                        (day)                                             
                             Rate Rate no effect                          
__________________________________________________________________________
Acne    257       2     7    72.8%                                        
                                  100% 0                                  
        64                   0    100% 0                                  
Eczema  267       2     7    1005 100% 0                                  
Pustule and                                                               
        141       2     7    97.9%                                        
                                  100% 0                                  
running                                                                   
sore                                                                      
Headsore                                                                  
        94        2     7    86.2%                                        
                                  97.8%                                   
                                       2.2%                               
Bedsore 61        2     7    96.7%                                        
                                  100% 0                                  
Flatwart                                                                  
        147       2     7    90.5%                                        
                                  98.6%                                   
                                       1.4%                               
Sharp   62        2     2 × 7                                       
                             67.7%                                        
                                  100% 0                                  
rheumatic                                                                 
Milliary                                                                  
        194       2     2    100% 100% 0                                  
vesicle                                                                   
Carbuncle                                                                 
        39        2     4 × 7                                       
                             53.8%                                        
                                  100% 0                                  
Beriberi                                                                  
        264       2     4 × 7                                       
                             97.1%                                        
                                  100% 0                                  
Plica   241       2     7    75.9%                                        
                                  1005 0                                  
Macula  45        2     7    100% 100% 0                                  
Urticaria                                                                 
        42        2     7    100% 100% 0                                  
Pudendaitch                                                               
        264       2     7    100% 100% 0                                  
Skin ulcer                                                                
        48        2     7    100% 100% 0                                  
Poisonous                                                                 
        199       2     1    93.9%                                        
                                  100% 0                                  
bee and                                                                   
tussokmoth bite                                                           
__________________________________________________________________________
Embodiment III-I
100 Kg of goldthread root, 60 Kg of yellow-croktree bark, 50 Kg of rhubarb, 100 Kg of scutellaria root and 90 Kg of pricklyash peel were mixed and cracked into particles with an average size of 2000 meshes. The particles were soaked for 6 hours and then finely ground to an average sized of 2 μm or below. 40 g of enzymes were added to give a specific activity concentration of 800 IU/g substrate. The enzymes were composed of 36% of cellulase, 22% of protease, 32% of amylase, 1% of lipase and 9% of lysozyme. The enzyme treatment was made at 75° C. for 48 hours. After the enzyment treatment, the mash was finely ground again. The ground mash was then filtered. The filtrate was sterilized in the same way as Embodiment I-1. The sterilized mash may be formulated for different applications, such as, lotions, oniments or creams, etc. for madication of skin, and the sterilized mash may also be concentrated and dried to form a product which may be used in fomulations of tablets, capsules or bath formulation, etc.
According to the present invention, a herbal medicine, comprising 5 to 40% of flavescent sophora root, 10 to 55% of stemona root, 10 to 35% of cnidium fruit, 5 to 60% of portulaca, 10 to 40% of gentian root and 5 to 60% of goldthread root, is prepared by the process of the present invention. The herbal medicine has application for treating various itches caused by, for example, skin dry, immunity endocrine uneguililium, or physical or chemical allergy. It can also inhibit itches caused by various tumors, psoriasis and neurodermatitis.
The deliver way may be transdermal absorption, oral or injection. It can be used to cure itch caused by dry, immunity endocrine umeguililium, or physical/chemical allergy.
For oral administration, the herbal medicine is administrated in the range of 10 to 30 mg per kilogram body weight per day and the daily dose is divided into four individual doses.
For injection administration, the herbal medicine is administrated in the range of 1 to 4 mg per kilogram body weight per day and the daily dose is divided into two individual doses.
Toxicity:
a. acute toxicity: LD50 on mise by intravenous injection is 0.15 g/kg(converted to dry powder), oral medication is 0.9 g/kg.
b. subacute toxicity: experimental result on rabbit(500±100 g)proved that there was no toxic symptom when 20 mg. of the drag delivered to the rectum of rabbit.
                                  TABLE 8                                 
__________________________________________________________________________
Experimental results of feeding animals                                   
     The amount                                                           
            Way of                                                        
                 Dosage                                                   
                      Duration    Result                                  
Group                                                                     
     of animal                                                            
            deliver                                                       
                 (mg/kg)                                                  
                      (day)                                               
                           Weight                                         
                               Diet                                       
                                  activity                                
                                      Deficating                          
                                            Death                         
__________________________________________________________________________
Watch                                                                     
     30     Rectum                                                        
                 30   7    +   +  +   +     0                             
Control                                                                   
     10     rectum                                                        
                 1 pill                                                   
                      7    +   -  -   -     0                             
__________________________________________________________________________
 Note (a) Control group are fed with multivitamin b pill (100 mg/per pill)
 (b) "+" stands for increase, "-" stands for normal                       
 c. Teratogenicity feeding experiment on mise for 6 months does not show  
 toxic teratogeny symptom.
c. Teratogenicity feeding experiment on mise for 6 months does not show toxic teratogeny symptom.
                                  TABLE 9                                 
__________________________________________________________________________
Experimental results from injection in animals                            
     The amount                                                           
            Way of                                                        
                 Dosage                                                   
                      Duration    Result                                  
Group                                                                     
     of animal                                                            
            deliver                                                       
                 (mg/kg)                                                  
                      (day)                                               
                           Weight                                         
                               Diet                                       
                                  activity                                
                                      Deficating                          
                                            Death                         
__________________________________________________________________________
Watch                                                                     
     30     Vein 20   7    ↑                                        
                               -- --  --    0                             
Control                                                                   
     10     Vein 1 tube                                                   
                      7    ↑                                        
                               -- --  --    0                             
                 (2 ml)                                                   
__________________________________________________________________________
 Note: (a) Injection water is used for control group                      
 (b) "↑" stands for increase, "--" stands for normal, "↓"    
 stands for decent
Pharmacology:
1. Effect of antibacterial and antiprotozoon
(a) Bacteria The herbal medicine can inhibit the growth or destroy hemolytic streptococcus, emningococcus, pneumococcus, vibriocholera, bacillus anthracis, staphylococcus aureus, bacillus dysenteriae, corynebacterium diphtheria, hay bacillus, streptococcus viridans, pneumobacillus, bordetella pertussis, bacillus pestis, bruceliar, clostriddium tetani, bacillus perfringens, tubercle bacilli, bacillus, proteus, bacterium coli, typhoid bacillus, bacillus pyocyaneus, etc., the mechanism is that it can inhibit the formation of DNA/RNA and protein of bacteria, strengthen the engulfing ability of white cell, T lymphocyte cell and liver reticuloendothelial system.
(b) Fungus It has a capacity of destroying various dermatomyces and also can kill leptospira;
(c) Protozoon It can inhibit and destroy ameba protozoon, trichomonad, leishmania donovani, trypanosome, paramecium etc.;
(d) Virus It can inhibit XINCHENG virus, influenza virus and PR8, smallpox virus and rabies virus can enable chicken embryo cultured with XINCHENG virus to survive more than 20 hours. It can also inhibit various pollen viruses.
2. Anti-inflammation and anti allergic reaction
(a) It can impair zymoexciting system (SH enzyme) of mastocyte, inhibit release of anaphylactin, have a effect of remitting the hypersensitive contraction/asthma of extracorporeal/in vivo trachea, can inhibit passive cutaneous anaphylaxis and histamine reaction;
(b) It can inhibit hypersensitive inflammation and edema, lower permeability of capillary, prevent mise from bleeding reaction caused by low atmospheric pressure.
(c) It can decompose the diseased skin cells, recover the wizened skin caused by physiological water lost, and improve the normal cells to hyperplasia properly.
3. Antipyretic Effect It has an effect on febrile rabbit caused by physical or chemical method, but no effect on normal rabbit.
Clinical trials show that the herbal medicine can cur itches caused by various disease except itches caused by psoriasis and tumors. The clinical trials were made by administrating the medicine on skin and the results are shown on Table 10.
              TABLE 10                                                    
______________________________________                                    
Summary of curative effect of clinical test on human body                 
                                     Cura-                                
                                     tive                                 
              Number Dura-           effect                               
              Complica- of times                                          
                               tion  Cure  Effect                         
Group Cases   tion      (day)  (day) rate  rate                           
______________________________________                                    
Itch  419               1      7     83.3% 100%                           
                               4 × 7                                
                                     94.3% 100%                           
      314     Rough skin                                                  
                        1      4 × 7                                
                                     79.9% 100%                           
      71      Plump skin                                                  
                        1      4 × 7                                
                                     84.5% 100%                           
      397     Cutin skin                                                  
                        1      4 × 7                                
                                     100%  100%                           
      274     Crumbs    1      4 × 7                                
                                     100%  100%                           
      191     Wizened   1      4 × 7                                
                                     100%  100%                           
              skin                                                        
      152     Redfeacks 1      7     100%  100%                           
      84      Papule    1      7     100%  100%                           
      95      Pustule and                                                 
                        1      7     100%  100%                           
              running                                                     
              sore                                                        
      62      Lymphom-  1      4 × 7                                
                                     100%  100%                           
              atosis                                                      
      41      Subcu-    1      4 × 7                                
                                     75.6% 97.6%                          
              taneous                                                     
              purpura                                                     
______________________________________                                    
 Note: Itches caused by tumors and psoriasis are no included.
Embodiment IV-1
15 Kg of flavescent sophora root, 15 Kg of stemona root, 15 Kg of cnidium fruit, 16 Kg of portulaca, 15 Kg of gentian root and 10 Kg of goldthread root were mixed and cracked into particles with an average size of 100 mashes. The particles were soaked for 24 hours and then were finely ground to form a mash having particles of an average size of 5 μm or below. 4 g of enzymes were added to give a specific activity concentration of 16 IU/g substrate. The enzymes were composed of 30% of cellulase, 25% of protease, 25% of amylase, 10% of lipase, 2% of lysozyme, 4% of glucase peptidase and 4% of peptichainase. The enzyme treatment was made with stirring at 30° C. for 90 hours. The enzyme-treated mash was finely ground again. The ground mash was filtered. The residue rate was 1.4%. The filtrate was then sterilized. The sterilized mash may be formulated for medical applications to skin. The mash may be concentrated and dried to give a product which may be used in preparation for oral or parenteral administration, such as, capsules, tablets and injections etc.
According to the present invention, a herbal medicine comprising 10 to 70% of goldenlarch bark, 5 to 50% of goldthread root, 5 to 50% of flavescent sophora root, 5 to 60% of stemona root, 5 to 60% of white cloves, 5 to 40% of pricklyash peel, 5 to 70% of oldenlandia and 5 to 30% of portulaca is prepared by the process of the present invention. The herbal medicine is administrated for treating diseases, for example, intractable itches such as, psoriasis, neurodermatitis, obstinate tinea, and viral itches such as, syphilis, gonorrhea and herpes zoster.
For oral administration, the herbal medicine is administrated in the range of 5 to 30 mg per kilogram body weight per day and the daily dose is divided into four individual doses.
For injection administration, the herbal medicine is administrated in the range of 0.5 to 5 mg per kilogram body weight per day and the daily dose is divided into two individual doses.
Toxicity:
LD50 by oral taking on mise is 1.2 g/kg, LD50 by injection on mise is 0.2 g/kg, and it has no sub and teratogenic toxicity.
                                  TABLE 11                                
__________________________________________________________________________
Experimental results from feeding animals                                 
     The amount                                                           
            Way of                                                        
                 Dosage                                                   
                      Duration    Result                                  
Group                                                                     
     of animal                                                            
            deliver                                                       
                 (mg/kg)                                                  
                      (day)                                               
                           Weight                                         
                               Diet                                       
                                  activity                                
                                      Deficating                          
                                            Death                         
__________________________________________________________________________
Watch                                                                     
     30     Rectum                                                        
                 30   7    ↑                                        
                               ↑                                    
                                  --  --    0                             
Control                                                                   
     10     rectum                                                        
                 1 pill                                                   
                      7    ↑                                        
                               -- --  --    0                             
__________________________________________________________________________
 Note (a) Control group are fed with multivitamin pill (100 mg/per pill)  
 (b) "↑" stands for increase, "--" stands for normal, "↓"    
 stands for decent                                                        

                                  TABLE 12                                
__________________________________________________________________________
Experimental results form injection in animals                            
     The amount                                                           
            Way of                                                        
                 Dosage                                                   
                      Duration    Result                                  
Group                                                                     
     of animal                                                            
            deliver                                                       
                 (mg/kg)                                                  
                      (day)                                               
                           Weight                                         
                               Diet                                       
                                  activity                                
                                      Deficating                          
                                            Death                         
__________________________________________________________________________
Watch                                                                     
     30     Vein 5    7    +   -  -   -     0                             
Control                                                                   
     10     Vein 1 tube                                                   
                      7    +   -  -   -     0                             
                 (2 ml)                                                   
__________________________________________________________________________
 Note: (a) Injection water is used for control group                      
 (b) "+" stands for increase, "-" stands for normal.
Pharmacology:
1. Effects of antimicrobial and antiprotozoon
(a) Bacteria The herbal medicine can inhibit the growth or destroy hemolytic streptococcus, meningococcus, pneumococcus, vibriocholera, bacillus anthracis, staphylococcus aureus, bacillus dysenteriae, corynebacterium diphtheria, hay bacillus, streptococcus viridans, pneumobacillus, bordetella pertussis, bacillus pestis, brucellar proteus, bacterium coli, typhoid bacillus, bacillus pyocyaneus, etc., the mechanism is that it can inhibit the formulation of DNA/RNA and protein of bacteria, strengthen the engulfing ability of white cell, T lymphocyte cell and liver reticuloendothelial system.
(b) Fungus It can destroy various dermatomyces and also can kill leptospira;
(c) Protozoon It can inhibit and destroy ameba protozoon, trichomonad, leishmania donovani, trypanosome, paramecium etc.;
(d) Virus It can inhibit XINCHENG virus, influenza virus and it can also effectively inhibit hepatitis virus, such as hepatitis A, B, C, etc. and specific virus, such as, herpes zoster and syphilis etc.
2. Anti-inflammation and anti allergic reaction
(a) It can impair zymoexciting system (SH enzyme) of mastocyte inhibit release of anaphylactin, have an effect of remitting the hypersensitive contraction/asthma of extracorporeal/in vivo trachea can inhibit passive cutaneous anaphylaxis and histamine reaction;
(b) It can inhibit hypersensitive inflammation and edema, lower permeability of capillary, prevent mise from bleeding reaction cause by low atmospheric pressure.
(c) It can decompose the diseased skin cells, recover the wizened skin caused by physiological water lost, and improve the normal cells to hyperplasia properly.
3. Effect of Anticancer, Antiration and Cellular Motablism It can inhibit the formation of DNA/RNA of cancer cell, check the growth of various tumor, have a direct destroying effect on mise's sarcoma, melanoma, mastadenoma and ascites carcinoma cell.
Clinical practice proved that using product to do medical treatment in the way described above has a obvious curative effect on vrius caused skin disease, such as psoriasis, neurodenma-titis, syphilis, gonorrhea and hypes zaster and erysipelas.
The curative effect is as follows:
1. It effectively destroy Treponema pallidum virus, psoriasis serum factor, killing gonorrhea pathogenic bacteria and other pathogenic microorganisms.
2. It can repair traumatic epidermis and teleneuron, make subcutaneous nodes soften and disappear, and recover the normal functions of epidermis and traumatic nerves by means of clearing cells with pathologic changes and speading the proliferation of normal cells; such as function is mainly realized by improving the DNA/RNA repair operated by secretory enzymes in cells.
3. Its clinical curative rates of syphilis and gonorrhea is essentially the same as those by present Western and Chinese medical methods; in views of "retrogressive irreversible pathologic changes, it also shows higher curative rate (up to over 90%), which is an advantage over the traditional medical
                                  TABLE 13                                
__________________________________________________________________________
Summary of curative effect on intractable itches                          
                        Number    Curative                                
                        of time   effect                                  
Transdermal        Dosage                                                 
                        (time/                                            
                             Duration                                     
                                  Cure                                    
                                      Effective                           
                                           Rate of                        
method Disease Cases                                                      
                   (g./day)                                               
                        day) (day)                                        
                                  rate                                    
                                      rate no effect                      
__________________________________________________________________________
Immersion                                                                 
       Psoriasis                                                          
               181 15 g 2    3 × 30                                 
                                  85.1%                                   
                                      100% 0                              
       Neurodermatitis                                                    
               54  15 g 2    3 × 30                                 
                                  96.3%                                   
                                      100% 0                              
       Obstinate tinea                                                    
               11  15 g 2    3 × 30                                 
                                  63.6%                                   
                                      100% 0                              
       Syphilis                                                           
               15  15 g 2    3 × 7                                  
                                  100%                                    
                                      100% 0                              
       Gonorrhea                                                          
               21  15 g 2    2 × 7                                  
                                  100%                                    
                                      100% 0                              
Applying                                                                  
       Psoriasis                                                          
               196      2    3 × 30                                 
                                  37.8%                                   
                                      94.3%                               
                                           5.7%                           
       Neurodermatitis                                                    
               47       2    3 × 30                                 
                                  59.6%                                   
                                      100% 0                              
       Obstinate tinea                                                    
               48       2    3 × 30                                 
                                  45.8%                                   
                                      95.8%                               
                                           4.2%                           
on skin                                                                   
       Hypes zaster                                                       
               28       2    4    100%                                    
                                      100% 0                              
       and erysiplas                                                      
Oral + Posriasis                                                          
               161 15 + 400                                               
                        2 + 4                                             
                             3 × 30                                 
                                  90.1%                                   
                                      100% 0                              
Applying                                                                  
       Neurodermatitis                                                    
               43  15 + 400                                               
                        2 + 4                                             
                             3 × 30                                 
                                  97.7%                                   
                                      100% 0                              
on skin                                                                   
__________________________________________________________________________
Embodiment V-I
4 Kg of goldenlarch bark, 1.5 Kg of goldthread root, 1 Kg of flavescent sophora root, 0.5 Kg of stemona root, 1.2 Kg of white cloves, 0.5 Kg of pricklyash peel, 0.8 Kg of oldenlandia and 0.5 Kg of portulaca were mixed and cracked into particles with an average size of 800 meshes. The particles were soaked for 30 hours and then finely ground to form mash having an average particle size of 10 μm or below. 0.5 g of enzymes were added to give a specific activity concentration of 6 IU/g substrate. The enzymes were composed of 40% of cellulase, 25% of protease, 25% of amylase, 3% of lipase, 4% of lysozyme, 1% of glucase peplidase and 2% of peptichainase. The enzyme treatment was made with stirring at 45° C. for 144 hours. The enzyme-treated mash was freely ground again. The ground mash was filtered and the filtrate was sterilized. The residue rate was 3˜7%. The sterilized mash may be formulated to applications on skin, such as, tincture, creams or lotions etc., and the sterilized mash may be spray dried to give a product which may be used in formulations for oral administration or of bath solution.
According to the present invention, a herbal medicine comprising 10˜70% of poria, 1˜30% of pinellia tuber, 5˜50% of pilose asiabell root, 1˜50% of immature bitter orange, 5˜40% of green tangerine orange peel, 1˜30% of atractylodes rhizome, 1˜25% of fresh ginger, 5˜40% of oldenlandia and 5˜40% of lonicera japonica flower, is prepared by the process of the present invention. The herbal medicine is used for treating diseases, such as, angina and pharyngitis, cardiatitis, esophagitis, enterogastritis, gastroenter ulcer, haemorrhoids, constipation, berhia, dyspepsia gastroenterli and gastroentercancer and other various tumor affections in the system, etc.
For oral administration, the herbal medicine is administrated in the range of 10 to 40 mg per kilogram body weight per day and the daily dose is divided into four individual doses.
For injection administration, the herbal medicine is administrated in the range of 1 to 5 mg per kilogram body weight per day and the daily dose is divided into two individual doses.
Toxicity:
LD50 by oral taking on mise is 50 g/kg, it has no up-limit and has no sub and teratogenic toxicity.
                                  TABLE 14                                
__________________________________________________________________________
Experimental results of animals                                           
The                                                                       
amount    Way of                                                          
               Dosage                                                     
                    Duration                                              
                         Result                                           
Group                                                                     
     of animal                                                            
          deliver                                                         
               (mg/kg)                                                    
                    (day)                                                 
                         Weight                                           
                             Diet                                         
                                activity                                  
                                    Deficating                            
                                          Death                           
__________________________________________________________________________
Watch                                                                     
     30   Rectum                                                          
               30   7    +   +  -   -     0                               
Control                                                                   
     10   Rectum                                                          
               1 pill                                                     
                    7    +   -  -   -     0                               
Watch                                                                     
     30   Vein  5   7    +   -  -   -     0                               
Control                                                                   
     10   Vein 1 tube                                                     
                    7    +   -  -   -     0                               
               (2 ml)                                                     
__________________________________________________________________________
 Note:                                                                    
 (a) Control group are fed with multivitamin pill (100 mg/per pill)       
 (b) Injection water is used for control group                            
 (c) "+" stands for increase, "-" stands for normal.
Pharmacology:
1. Effects of antimicrobial and antiprotozoon
(a) Bacteria The herbal medicine can inhibit the growth or destroy hemolytic streptococcus, meningococcus, bacillus anthracis staphylococcus aureus, bacillus dysenteriae, bacterium coli, bacillus pyocyaneus, etc.,
(b) Protozoon It can inhibit and destroy ameba protozoon, trichomonad, leishmania donovani, trypanosome, paramecium etc..
2. Anti-inflammation and anti allergic reaction
(a) It can impair zymoexciting system (SH enzyme) of mastocyte, inhibit release of anaphylactin, and can inhibit passive anaphylaxis and histamine reaction;
3. Effect of Anticancer, Antiradiation and Cellular Motablism It can inhibit the protein synthesis of DNA/RNA of cancer and has a direct damaging effect on ascitic canceration. But it has no effect on normal cells.
4. Decompose of stone It can decompose gastroenterlith through to destroy the network of protein in gastroenterlith.
Clinical trial shows that the herbal medicine administrated by oral or transdermal methods has obvious curative effects on various diseases of gastroenteric system, such as, angina and pharyngitis, cardiatitis, esophagitis, gastroenteritis, gastroenter ulcer, haemorrhoids, constipation berhia, dyspepsia, gastroenterli and gastroenter cancer, etc.
The cure rate is higher than 85%, and effective rate is higher than 97%. It has a good inhibiting and curative effects on various tumor canceration of digestive system, such as, cardia cancer, laryngocarcinoma and gastroenteric cancer, etc.. The effective rate is higher than 80%.
                                  TABLE 15                                
__________________________________________________________________________
Summary of curative effect of clinical test on human body                 
                                  Curative                                
Way                    Number of  effect                                  
of               Dosage                                                   
                       time  Duration                                     
                                  Curative                                
                                       Effective                          
deliver      Cases                                                        
                 (mg/time)                                                
                       (time/day)                                         
                             (day)                                        
                                  Rate Rate                               
__________________________________________________________________________
Transder                                                                  
     Gastroenter                                                          
             293 15000 1     30   100% 100%                               
mal  ulcer                                                                
     Gastroenteritis                                                      
             299 15000 1     30   92.4%                                   
                                       100%                               
     Haemorrhoids                                                         
             151 15000 1     30   86.3%                                   
                                       100%                               
     Cardiatitis                                                          
             146 15000 1     30   100% 100%                               
     Constipation                                                         
             132 15000 1     30   100% 100%                               
Oral Gastroenter                                                          
             152 400   4     30   94.7%                                   
                                       100%                               
     ulcer                                                                
Oral Gastroenteritis                                                      
             194 400   4     30   94.7%                                   
                                       100%                               
     Haemorrhoids                                                         
              67 400   4     30   91.0%                                   
                                       100%                               
     Cardiatitis                                                          
              34 400   4     30   91.2%                                   
                                       100%                               
     Enterolith                                                           
              57 400   4     30   100%                                    
     Constipation                                                         
              86 400   4     30   100%                                    
__________________________________________________________________________
Embodiment VI-1
20 Kg of poria, 7 Kg of pinellia tuber, 8 Kg of pilose asiabell root, 13 Kg of immature bitter orange, 10 Kg of green tangerine orange peel, 10 Kg of atrac tylodes rhizome, 12 Kg of fresh ginger, 10 Kg of oldenlandia and 10 Kg of lonicera japonica flower were mixed and cracked into particles with an average size of 300 mashes or below. The particles were soaked for 5 hours and finely ground to form a mash with an average particle size of 5 μm or below. 30 g of enzymes were added to give a specific activity concentration of 400 IU/g substrate. The enzymes were composed of 20% of cellulase, 10% of protease, 37% of amylase, 11% of lipase, 10% of lysozyme, 4% of glucase peptidase and 8% of peptichainase. The enzyme treatment was made with stirring at 75° C. for 72 hours. The enzyme-treated mash was then finely ground again and was filtered. The residue rate was 2.4%. The filtrate was sterilized. The sterilized mash may be formulated to give oral liquid The sterilized mash may also be, after dried, prepared for various medical applications in formulations such as, pellets, capsules, tablets, powders or both formulations, etc.
According to the present invention, a herbal medicine comprising 5˜50% of Chinese yam, 5˜65% of pueraria root, 10˜70% of poria, 5˜75% of dried rehmannia root, 5˜60% of wolfberry fruit, 5˜50% of pollen, 5˜40% of rhizoma alismatis, 1˜35% of mulberry leaf, 1˜50% of lotus leaf, 1˜50% of atractylodes rhizome, 0˜35% of cherokee rose-hep and 5˜65% of black plum is prepared by the process of the present invention. The herbal medicine is used for treating diseases such as diabetes mellitus.
For oral administration, the herbal medicine is administrated in the range of 10 to 50 mg(for NIDDM patients: 10 to 30 mg, IDDM patients: 20 to 50 mg, Cancer patients: 40 to 50 mg) per kilogram body weight per day and the daily dose is divided into four individual doses.
For injection administration, the herbal medicine is administrated in the range of 1 to 10 mg(for NIDDM patients: 1 to 4 mg, IDDM patients: 3 to 10 mg, Cancer patients: 6 to 10 mg) per kilogram body weight per day and the daily dose is divided into two individual doses.
Toxicity:
LD50 by oral taking on mice is 12 g/kg, LD50 by injection is 12 g/kg, and it has no sub and teratogenic toxicity.
                                  TABLE 16                                
__________________________________________________________________________
Experimental results from feeding animals                                 
The                                                                       
amount    Way of                                                          
               Dosage                                                     
                    Duration                                              
                         Result                                           
Group                                                                     
     of animal                                                            
          deliver                                                         
               (mg/kg)                                                    
                    (day)                                                 
                         Weight                                           
                             Diet                                         
                                activily                                  
                                    Defecating                            
                                          Death                           
__________________________________________________________________________
Watch                                                                     
     30   Rectum                                                          
               30   7    +   +  -   -     0                               
Control                                                                   
     10   rectum                                                          
               1 pill                                                     
                    7        -  -   -     0                               
__________________________________________________________________________
 Note:                                                                    
 (a) Control group are fed with multivitamin pill (100 mg/per pill        
 (b) "+" stands for increase, "-" stands for normal.
Note:
(a) Control group are fed with multivitamin pill (100 mg/per pill)
(b) "+" stands for increase, "-" stands for normal.
                                  TABLE 17                                
__________________________________________________________________________
Experimental results from injection in animals                            
The                                                                       
amount    Way of                                                          
               Dosage                                                     
                    Duration                                              
                         Result                                           
Group                                                                     
     of animal                                                            
          deliver                                                         
               (mg/kg)                                                    
                    (day)                                                 
                         Weight                                           
                             Diet                                         
                                activily                                  
                                    Defecating                            
                                          Death                           
__________________________________________________________________________
Watch                                                                     
     30   Vein 5    7    +   -  -   -     0                               
Control                                                                   
     10   Vein 1 tube                                                     
                    7    +   -  -   -     0                               
               (2 ml)                                                     
__________________________________________________________________________
 Note:                                                                    
 (a) Injection water is used for control group                            
 (b) "+" stands for increase, "-" stands for normal,
Pharmacology:
1. Anti-inflammation and anti allergic reaction
(a) The herbal medicine can inhibit zymoexciting system (SH enzyme) of mastocyte.
(b) It can inhibit inflammation and edema.
(c) It can improve cell activity of white cell, T lymphocyte cell and liver reticuloendothelial system.
2. It can improve the activity and endocrine function of liver cell, kidney cell, adrenfal gland cell, pancreas cell and pancreas islet cell, and promote the equilibrium of the secretion of adrenaline insulin, demethyl adrenaline and other physiological enzymes (hormone) to the normal conditions.
3. Effect of Anticancer, Antiradiation and Cellular Metabolism
It can inhibit the synthesis of DNA/RNA of cancer cell and other genvariated cell, can accelerate the synthesis of DNA/RNA of normal cell to rehabilitate the normal organizational structure and function of paraorgan.
Clinical practice proved that using product to do medical treatment in the way of transdermal absorption or oral medication has a obvious curative effect on diebate:
1. It is not necessary to control the weight of meal and carbohydrate, but it is necessary to make sure not to take any foods which contain, such as preservative substance, antiseptic, nitrite, agricultural chemical, and other cytotoxicity food, high salt food and the food containing single/dual glucose more than 50%.
2. It has obvious and widely curative effect on the complications caused by diabetes and any other diseases of endocrine system-such as glomerulonephropathy, thyropathy, gall bladder disease, hepatic disease, prostale gland disease, pancreas disease fenoglamerulone-nephro HBP (high blood pressure), hyperglycemia, hyperlipemia, hypematremia, hyperkalemia, coronary heart disease, arteriosclerosis, retinopathy, optic nerve damage, ending neuritis movement disorder of nerves motorius or autonomic nerve, etc. The cure effect is higher than 85%.
3. After treatment about 2˜4 months, the organization structure and physiological function of the pathological changed organs can be recovered to normal conditions. For example, patients can recover from glomeruli, renal pelvis, damages, nerves opticus damages and pancreas damages.
4. It can recover the organization structure of pancreas to normal conditions, equilibrium the secretion rate of insulin and other hormones, keep the blood glucose rate as normal man, and urea glucose clear.
5. According to the following method to treat and nurse NIDDm and IDDm patients, the cure effect rate is higher than 75% and effect rate reaches to 97%.
I. NIDDm patients
a. The patients who use drugs such as dibotion, glucophage etc., without hormone agent, shall stop further using the drugs after they begin to use the herbal medicine of the present invention.
b. The patients who use the drugs such as Dibotin, Glucophage etc. with hormone agent, can begin to decrease the dosage of the drugs in the proportion of 20% each 5˜7 days from a week after they begin to use the herbal medicine of the present invention, and the patients will stop using the drugs in a month after they take the herbal medicine.
c. The patients who use the drugs such as D860, diabinese Glyburide, Diamicron, Glutril, Glurenorm etc., can begin to decrease 20% of the dosage of the drugs, in first 5 to 7 days after they take the herbal medicine of the present invention, and drop 20% each 5 days after first decrease (in practice, the proportional is according to the rehabilitation of the secretion level of insulin).
II. IDDM patients
a. The dosage of insulin would be decreased 20% within first 5˜7 days after the herbal medicine is taken and then decreased 20% each 5˜10 days. And no insulin will be taken after 70˜10 weeks. In practice, the decreasing of the dosages may be according to the rehabilitation of the secretion of insulin of himself.
After stop using insulin, keep this dosage for 1-2 months, and then the dosage drops to 200-400 mg/time, 4 times/day after all characters of endocrine, special insulin, C-peptide, BL-GLU, U-GLU, are became normal, and the organization structure and secretion function of pancreas are shown in substantially normal conditions
6. It has supplementary theriputicl effects on diseases of endocrine system and diseases related to endocrine, such as, itch, hypertension, hyperlipemia, hyperplasia of mammary glands and canceration reproductive system.
7. Has a direct destroying effect or inhibiting effect on cancer of brain, liver, kidney, bowel and stomach, lungs and bonds etc.
                                  TABLE 18                                
__________________________________________________________________________
Summary of curative effects of clinical test on human body                
                     Number    Curative                                   
Way              Dosage                                                   
                     of time   effect                                     
of               (mg/                                                     
                     (time/                                               
                          Duration                                        
                               Curative                                   
deliver                                                                   
      Group  Cases                                                        
                 time)                                                    
                     day) (day)                                           
                               Rate Effective                             
                                         Rate                             
__________________________________________________________________________
Immersion                                                                 
      NIDDM  64  15000                                                    
                     2    6 × 30                                    
                               79.7%                                      
                                    98.8%                                 
                                         100%                             
      IDDM   33  15000                                                    
                     1    6 × 30                                    
                               36.4%                                      
                                    87.8 100%                             
      Prostatitis                                                         
             54  15000                                                    
                     1    3 × 30                                    
                               98.1%                                      
                                    100% 100%                             
      Pancreatitis                                                        
             71  15000                                                    
                     1    3 × 30                                    
                               91.5%                                      
                                    100% 100%                             
      Cancer of                                                           
             37  15000                                                    
                     2    3 × 30                                    
                                    83.8%                                 
      endocrinium                                                         
Oral  NIDDM  116  600                                                     
                     4    6 × 30                                    
                               83.6%                                      
                                    98.3%                                 
                                         99.1%                            
      IDDM   194  800                                                     
                     4    6 × 30                                    
                               27.9%                                      
                                    95.3%                                 
                                         100%                             
      Prostatitis                                                         
             67   400                                                     
                     4    3 × 30                                    
                               84.8%                                      
                                    96.2%                                 
                                         100%                             
      Pancreatitis                                                        
             54   400                                                     
                     4    3 × 30                                    
                               96.2%                                      
                                    100% 100%                             
      Cancer of                                                           
             26   800                                                     
                     2    3 × 30                                    
                                    80.7%                                 
      endocrinium                                                         
__________________________________________________________________________
 Note:                                                                    
 1. The standard of the cure case is                                      
 a. BGLU: 3.9˜6.2 mmol/L, or BGLU < 11.0 mmol/L 2 hours after eating
 b. UGLU: normal all time;                                                
 c. the secretion of insulin: normal;                                     
 d. the characters of diebate: disappeared;                               
 e. the complications caused by diebate: disappeared;                     
 f. almost all relative hormone: normal.                                  
 2. Cancers of endocrinium mean cancers of brain, liver, kidney, prostate,
 gland, pancreas, lung, reproductive system (including womb, mammary      
 gland), etc.
Embodiment VII-1
11 Kg of Chinese yam, 9 Kg of pueraria root, 12 Kg of poria, 10 Kg of dried rehmannia root, 8 Kg of wolfberry fruit, 13 Kg of pollen, 6 Kg of rhizoma alismatis, 12 Kg of mulberry leaf, 6 Kg of lotus leaf, 7 Kg of atractylodes rhizome and 6 Kg of black plum were mixed and cracked into praticles with an average size of 300 mashes or below. The particles were soaked for 20 hours and finely ground to a size of 5 μm or less. 20 g of enzymes were added to give a specific activity concentration of 150 IU/g substrate. The enzymes were composed of 19% of cellulase, 22% of protease, 40% of amylase, 3% of lipase, 10% of lysozyme, 3% of glucase peptidase and 3% of peptichainase. The enzyme treatment was made with stirring at 55° C. for 100 hours. The enzyme-treated mash was finely ground again and filtered. The residue rate was 3%. The filtrate was then sterilized. The sterilized mash may be prepared to give oral solutions. After dried, the sterilized mash may be used in formulations, such as, pellets, tablets, eapsuals, powder or immersion formulations for administration to skin by immersion method etc.
According to the present invention, a herbal medicine comprising 5˜30% of oriental wormwood, 1˜25% of red sage root, 1˜30% of dandelion herb, 2˜25% of bupleurum root, 1˜20% of scutellaria root, 0˜40% of oldenlandia, 0˜35% of pollen, 0˜30% of wolfberry fruit, 1˜25% of mulberry leaf, 1˜25% of rhizoma alismatis is prepared by the process of the present invention.
For oral administration, the herbal medicine is administrated in the range of 10 to 25 mg(for Cancer patients: 20 to 40 mg) per kilogram body weight per day and the daily dose is divided into four individual doses.
For injection administration, the herbal medicine is administrated in the range of 1 to 4 mg(for Cancer patients: 3 to 8 mg) per kilogram body weight per day and the daily dose is divided into two individual doses.
Toxicity:
a. acute toxicity: LD50 on mise by intravenous injection is 2.5 g/kg(converted to powder), oral medication is 11.0 g/kg(dried powder).
b. subacute toxicity: experimental result on rabbit(500±100 g) proved that there was no toxic symptom when 20 mg of the drug delivered to the rectum of rabbit.
c. Teratogenicity feeding experiment on mise for 6 months, does not show toxic teratogeny symptom.
                                  TABLE 19                                
__________________________________________________________________________
Experimental results of feeding and injection in animals                  
The                                                                       
amount    Way of                                                          
               Dosage                                                     
                    Duration                                              
                         Result                                           
Group                                                                     
     of animal                                                            
          deliver                                                         
               (mg/kg)                                                    
                    (day)                                                 
                         Weight                                           
                             Diet                                         
                                actively                                  
                                     Deficating                           
                                           Death                          
__________________________________________________________________________
Watch A                                                                   
     30   Rectum                                                          
               20   7    +   -  -    -     0                              
Control                                                                   
     10   rectum                                                          
               1 pill                                                     
                    7    +   -  -    -     0                              
Watch B                                                                   
     30   Vein  5   7    +   -  -    -     0                              
Control                                                                   
     10   Vein 1 tube                                                     
                    7    +   -  -    -     0                              
               (2 ml)                                                     
__________________________________________________________________________
 Note:                                                                    
 (a) Control group A are fed with multivitamin pill (100 mg/per pill)     
 (b) Injection water is used for control B                                
 (c) "+" stands for increase, "-" stands for normal
Pharmacology:
1. Effect of antibacterial and antimicrobiol
(a) Bacteria The herbal medicine can inhibit the growth of hemolytic Streptococcus, Pneumococcus, Staphylococcus aureus, Bacillus dysentefiae, Corynebactefium diphtheria, Pneumobacillus, bovine or human tubercle Bacilli, etc.
(b) Fungus and protozoon It can inhibit the growth of various dermatomyces and also can anaesthetize roundworm and earthworm.
(c) Virus It can inhibit and destroy, influenza virus RP8, hepatitis B virus and E CH0 11 virus.
2. Cholagogic Effect It can increase the volume of biliation of dog and rabbit, have conspicuous effect of inhibiting intestinal canal, and not related to vagus nerve;
3. Effect to experimental hepatitis It can decrease the death rate of rabbits and mise with hepatitis caused by CCL4 poisoning; the cholagogic effect are more effective to dogs with hepatitis by poisoning than other normal dogs. It can also rehabilitate HIV-level of CCL4 poisoned rabbits or dogs to normal, and stimulate their appetite. Forthermore, it can decrease the death rate and pathologic change of hepacell to experimental animals with viral hepatitis, and improve the recreation of hepacell.
4. Antipyretic Effect It has an antipyretic effect on febrile experimental animals (such as rabbits and dogs), but no effect on normal rabbit;
5. Diuretic Effect It can increase the urinary volume of domestic rabbits with toxic hepatitis and change the urea color from yellow to clear.
6. Effect of Anticancer It can inhibit the carcinoma of hepaascites, recreate sclerotic tissues, make ascites disappear and make neophastic cakings atrophy or disappear. (The mechanisms is to check the synthesis of DNA/RNA of neophastic cells and cells with pathologic changes)
7. Other Effects After administrated 2-3 weeks, it can decrease the ratios of serum cholesterol and low density lipoprotein increase the ratio of high density lipoprotein and have protection effect oh pathologic changes of aortic arch and internal organs.
Clinical practice proved that using product to do medical treatment in the way described above has a obvious curative effect on diseases, such as, virus acute and chronic hepatitis hepatitis, hepato-genous jaundice, cirrhosis and cancer of the liver, ect.
1. After 1-3 months of administration, the negative conversion rates of HBsAg, HBeAg, anti-HBcIgM, HOV-DNA, DNA-p ect. are over 80%.
2. Hepaascites disappear after 1-3 weeks of administration.
3. The rate of recovering to normal of plasmic A/G ratio prothrombin time, r-GT and serum bilirubin are over 75%.
                                  TABLE 20                                
__________________________________________________________________________
Summary of curative effect of clinical test on human body                 
                                 Curative                                 
                      Number of  effect                                   
Way of           Dosage                                                   
                      time  Duration                                      
                                 Cure                                     
                                     Effective                            
treatment                                                                 
     Disease Cases                                                        
                 (g./day)                                                 
                      (time/day)                                          
                            (day)                                         
                                 rate                                     
                                     rate                                 
__________________________________________________________________________
Immer-                                                                    
     Hepatitis A                                                          
             41  15000                                                    
                      1     4 × 7                                   
                                 92.6%                                    
                                     100%                                 
sion Hepatitis B                                                          
             139 15000                                                    
                      1     3 × 30                                  
                                 82.0%                                    
                                     94.2%                                
     Hepatitis E                                                          
             74  15000                                                    
                      1     3 × 30                                  
                                 90.5%                                    
                                     95.9%                                
     Hepatoginous                                                         
             24  15000                                                    
                      1     4 × 7                                   
                                 89.5%                                    
                                     100%                                 
     janndice                                                             
     Cirrhosisis                                                          
             77  15000                                                    
                      2     6 × 30                                  
                                 36.4%                                    
                                     84.8%                                
     Cancer of liver                                                      
             17  15000                                                    
                      2     3 × 30                                  
                                     76.7%                                
Oral Hepatitis A                                                          
             54   400 4     4 × 7                                   
                                 90.7%                                    
                                     100%                                 
     Hepatitis B                                                          
             213  400 4     3 × 30                                  
                                 83.1%                                    
                                     100%                                 
     Hepatitis E                                                          
             96   600 4     3 × 30                                  
                                 88.5%                                    
                                     96.8%                                
     Hepatoginous                                                         
             117  400 4     4 × 7                                   
                                 98.3%                                    
                                     100%                                 
     janndice                                                             
     Cirrhosisis                                                          
             41   600 4     6 × 30                                  
                                 41.5%                                    
                                     87.8%                                
     Cancer of liver                                                      
             49   800 4     3 × 30                                  
                                     53.0%                                
__________________________________________________________________________
 Note: the effective rate of cancer of the liver is the control rate only.
Embodiment VIII-1
20 Kg of oriental wormwood, 3 Kg of red sage root, 15 Kg of damdelion herb, 6 Kg of bupleurum root, 9 Kg of scutellaria root, 15 Kg of oldenlandia, 6 Kg of pollen, 6 Kg of wolfberry fruit, 8 Kg of mulberry leaf and 12 Kg of rhizoma alismatis were mixed and cracked into particles with an average size of 2000 meshes. The particles were soaked for 6 hours and finely ground to an average size of 2 μm or below. 6 g of enzymes were added to give a specific activity concentration of 8 IU/g substrate. The enzymes were composed of 29% of cellulase, 10% of protease, 45% of amylase, 2% of lipase, 8% of lysozyme, 3% of glucase peptidase and 3% of peptichainase. The enzyme treatment was made with stirring at 60° C. for 24 hours. The enzyme-treated mash was finely ground again and filtered and ultra-filtered. The residue rate was 2.2%. The filtrate was concentrated under vacuum and spray dried. The product is used in formulations for various medical applications.
According to the present invention, a herbal medicine comprising of 1˜30% of tetrandra root, 1˜20 % of ginseng, 5˜40% of cinnamom twig, 5˜30% of plaster stone, 5˜30% of lotus leaf, 5˜30% of mulberry leaf, 1˜25% of immature bitter orange and 1˜40% of Cherokee rose-hip is prepared by the process of the present invention.
For oral administration, the herbal medicine is administrated in the range of 5 to 10 mg per kilogram body weight per day and the daily dose is divided into four individual doses.
For injection administration, the herbal medicine is administrated in the range of 0.5 to 1 mg per kilogram body weight per day and the daily dose is divided into two individual doses.
Toxicity:
a. When oral administration or injection in exceptional dose (>10 g/kg), no toxic reaction occurs, except excitation and insomnia are observed.
b. No chronical teratogenic poisonousness and sub-acute poisonousness are observed.
Pharmacology:
1. Effect of antiphlogisty, analgesia and antiallergy The herbal medicine can reduce the permeability of blood vessels and decrease greatly the occurrence rate of serious shock sympton caused by holoalbumen and the death rate, have notable effect to Dutch pig histamine toxic shock; can also inhibit immune hemolysis, activate lymph node, increase weight and concentration of DNA/RNA in plasmablasts and plasmocytes, and increase the amount of such cells.
2. Effect to circulatory system It can be as hypotensor by intravenous injection, intramuscular injection or oral administration and the reduction of blood pressure can be 30˜65% and last longer than 2 hours without notable changes to systole, heart rate and blood transmission; can also expand blood vessels, strengthen acetylcholine's reduction effect to blood pressure, and inhibit or relieve the blood pressure boost caused by repressing aorta.
3. Effect to striated muscle It can relax striated muscle but have no notable effect to nerve block.
4. Effect to blood It can decrease greatly contents of serum cholesterol triglyoeride and low density lipoprotein and increase the ratio of high density lipoprotein after deliver for 1-2 weeks; can make the fat accumulation in liver and heart deereass or disappear.
5. Effect to anticancer It can inhibit Einstein's ascites carcinoma cells in small mouse and ascites carcinoma cells in big mouse, block their synthesis of DNA/RNA, strengthen phagocytic ability of leukocytes, T lymphocytes and endothelium network system in liver.
Clinical practice proved that using product made by the present Embodiment to cure cardio-cerebral and blood vessel diseases, such as hypertension, hyperlipemia, coronary heart disease, arteriosclerosis etc., decrease cholesterol, triglyceride and low density lipoprotein in blood, raise the content of high density lipoprotein, adjust blood viscosity and soften blood vessels. The effective rate is over 95%.
__________________________________________________________________________
          blood pressure                                                  
                  plasma concentration                                    
Patient A (mmHg)  (mPa · s)                                      
                             blood test                                   
__________________________________________________________________________
In the middle of                                                          
          100-120 2.54       T-CHOL       8.54                            
June, 1994                   mmocOC/L                                     
                             TG 2.46 mmocOC/L                             
                             β-LDL 63.8%                             
                             HDL-C 0.74 mmOC/L                            
After 1 week from                                                         
           80-120 1.36       T-CHOL 6.52 mmOC/L                           
administration of the        TG 1.83 mm OC/L                              
product of the               β-LDL 58.7%                             
present Embodiment           HDL-C 0.98% mmOC/L                           
on July 2, 1994                                                           
__________________________________________________________________________
Embodiment IX-1
12 Kg of tetrandra root, 10 Kg of ginseng, 16 Kg of cinnamom twig, 20 Kg of plaster stone, 18 Kg of lotus leaf, 18 Kg of mulberry leaf, 8 Kg of immature bitter orange and 10 Kg of cherokee rose-hip were mixed and soaked into particles with an average size of about 1000 meshes. The particles were cracked for 6 hours and finely ground to give a mash with an average partical size of 5 μm or below. 5 g of enzymes were added to give a specific activity concentration of 8 IU/g substrate. The enzymes were composed of 27% of cellulase, 24% of protease, 15% of amylase, 10% of pectase, 15% of hemicellulase, 4% of lysozyme, 3% of gulcase peptidase and 2% of peptichainase. The enzyment treatment was carried on with stirring at 50° C. for 24 hours. The enzyme-treated mash was finely ground again and filtered and ultrafiltered. The residue rate was 3%. The filtered mash was then sterilized and was then treated by an ultrasonic method and was then concentrated and dried to give a product. The product is to be used in formulations for various medical applications.
According to the present invention, a herbal medicine comprising 5˜30% of ginseng, 5˜30 % of astragahis root, 5˜40% of lotus leaf, 5˜35% of schizonepeta and 5˜25% of tetrandra root is prepared by the process of the present invention.
For oral administration, the herbal medicine is administration in the range of 10 to 30 mg per kilogram body weight per day and the daily dose is divided into four individual doses.
For injection administration, the herbal medicine is administration in the range of 1 to 2 mg per kilogram body weight per day and the daily dose is divided into two individual doses.
Embodiment X-1
10 Kg of ginseng, 10 Kg of lotus leaf, 10 Kg of schizonepeta and 10 Kg of tetrandra root were mixed and cracked into a particles with an average size of about 1200 meshes. The particles were soaked for 5 hours and finely ground to give a mash with an average partical size of 10 μm or below. 2 g of enzymes were added to give a specific activity concentration of 16 IU/g. The enzymes were composed of 10% of cellulase, 35% of protease, 15% of amylase, 10% of pectase, 15% of hemicellulase, 10% of lysozyme and 5% of glucase peptidase. The enzyme-treatment was made with stirring at 70° C. for 24 hours. The enzyme-treated mash was finely ground again, filtered and ultrafitered. The residue rate was about 2%. The filtered mash was then treated by an ultrasonic method, concentrated and dried to give a product. The product may be used in formulations for various medical applications.
Toxicity:
No adverse effects have been shown by taking a large amount for oral or injection, and no sub and teratogenic toxicity have been shown.
                                  TABLE 21                                
__________________________________________________________________________
Experimental results from feeding animals                                 
The       Way                                                             
amount    of   Dosage                                                     
                    Duration                                              
                         Result                                           
Group                                                                     
     of animal                                                            
          deliver                                                         
               (mg/kg)                                                    
                    (day)                                                 
                         Weight                                           
                             Diet                                         
                                activity                                  
                                    Deficating                            
                                          Death                           
__________________________________________________________________________
Watch                                                                     
     30   Rectum                                                          
               30   7    +   +  +   +     0                               
Control                                                                   
     10   rectum                                                          
               1 pill                                                     
                    7    +   -  -   -     0                               
__________________________________________________________________________
 Note:                                                                    
 (a) Control group are fed with multivitamin pill (100 mg/per pill)       
 (b) "+" stands for increase, "-" stands for normal.                      

                                  TABLE 22                                
__________________________________________________________________________
Experimental results from injection in animals                            
The       Way                                                             
amount    of   Dosage                                                     
                    Duration                                              
                         Result                                           
Group                                                                     
     of animal                                                            
          deliver                                                         
               (mg/kg)                                                    
                    (day)                                                 
                         Weight                                           
                             Diet                                         
                                activity                                  
                                    Deficating                            
                                          Death                           
__________________________________________________________________________
Watch                                                                     
     30   Vein 15   7    +   +  +   -     0                               
Control                                                                   
     10   Vein 1 tube                                                     
                    7    +   -  -   -     0                               
               (2 ml)                                                     
__________________________________________________________________________
 Note:                                                                    
 (a) Injection water is used for control group                            
 (b) "+" stands for increase, "-" stands for normal.
Pharmacology:
1. Effect to never system It can strengthen the exciting process or inhabit it, improve the activity of nerve system, anti-inhibit to the condition-inflection caused by ethanol and morphine. The anti-fatigue effect of animals is notable.
2. Disease resistance It can enhance the defend ability of body to a varity of harmful stimulation and prolong the live time of experimental animals, accelerate the rehabitation of animals.
3. Effect to the endocrime system It has notable anti-excitability effect; can strengthen the function of thyroid and sex gland and improve internal secratation unction.
4. Effect to the metabolism
a. It can improve the synthesis of DNA/RNA of normal cells;
b. It can improve blood glucose metabolism, and cause to decrease body's blood glucose by mainly improving the organ breathe, accelerating fermentation of glucose, rising the level of energy metabolism.
c. It has no effect on ratio of serum CHOL/total phospholipid of normal animal, can lower abnormal ratio of serum CHOL/T-psp.
5. Effect of Diuretin By oral or injection, it has effects diuretin, and can increase the Na+ draining.
6. Effect of Fatty Deposition It can effectively decrease T-CHOL, TG, LDL contains, raise HDL rate after delivering the herbal medicine for 1-6 weeks, at same time, can reduce the fatty volume of liver, heart or under skin.
7. Effect of Anticancer, Antiradiation and Cellular Motablism It can inhibit the formation of DNA/RNA of cancer cell, check the growth of various tumor.
Clinical practice proved that using product to medical treatment in the way described above has a obvious curative effect on obesity and emaciate.
              TABLE 23                                                    
______________________________________                                    
Summary of curative effect of clinical test human body                    
                                  Curative                                
Cases      Dosage  Number   Dura- effect                                  
       (per-   (g/per  of times                                           
                              tion  Cure  Effective                       
Group  son)    time)   (day)  (day) rate  rate                            
______________________________________                                    
Obesity                                                                   
       72      400     4      6 × 7                                 
                                    94.4% 100%                            
Emaciate                                                                  
       41      400     4      6 × 7                                 
                                    85.4% 100%                            
______________________________________                                    
 Note:                                                                    
 (a) "Obesity" herein means that the body weight exceeds the normal by ove
 40%.                                                                     
 (b) "Emacite" herein means that the body weight is less than the normal b
 over 25%, except emaciates caused by diabetes and other Chronic diseases.
 (c) "Cure" herein means that the body weight recovers into the range of  
 ±20% of the normal, and the fluctuation of body weight is less than   
 ±5% when the administration is stopped for 6 months.                  
 (d) "Effective" herein means that the body weight recovers over 10%, and 
 it has no significant fluctuation ( ≦ ±5%) after the           
 administration is stopped.

Claims (17)

What is claimed is:
1. A process for preparing a herbal medicine comprising the steps of:
forming a mash from raw material,
grinding finely the mash to make the size of average suspended particles less than 50 μm,
hydrolyzing the ground material by using a multi-enzyme system, the enzyme system comprising cellulases, proteases, amylases, lipases, and lysozymes and having an activity unit of from about 20,000 to about 10,000,000 IU/g, wherein the hydrolyzing takes place at a temperature of from about 20° C. to about 80° C., and
sterilizing the hydrolyzed material.
2. A process as claimed in claim 1, wherein the multi-enzyme system comprises 5-75% of cellulases, 5-50% of proteases, 5-50% of amylases, 1-20% of lipases and 1-15% of lysozyme.
3. A process as claimed in claim 2, wherein the hydrolysis takes place at temperature from about 20° C. to about 80° C. for about 5 hours to about 144 hours.
4. A process as claimed in claim 1, wherein the multi-enzyme system further comprises one or more supplementary enzymes.
5. A process as claimed in claim 1, wherein the process further comprises a step of filtering the hydrolyzed material before the sterilization step.
6. A process as claimed in claim 1, wherein the process further comprises a second finely grinding step after hydrolyzing the ground material.
7. A herbal medicine for treating diseases of humans and/or animals prepared by the process of claim 1.
8. A pharmaceutical formulation comprising an effective amount of the herbal medicine as claimed in claim 7 and a physiologically acceptable excipient and/or auxiliary.
9. A herbal medicine as claimed in claim 7, wherein the herbal medicine comprises 10˜40% of mahonia stem, 10˜40% of siegesbeckia herb, 5˜45% of sperankia stuberculata and 5˜30% of cnidium fruit.
10. A herbal medicine as claimed in claim 7, wherein the herbal medicine comprises 10˜35% of goldthread root, 10˜35% of yellow-corktree bark, 5˜50% of rhubarb, 5˜40% of scutellaria root and 1˜65% of pricklyash peel.
11. A herbal medicine as claimed in claim 7, wherein the herbal medicine comprises 5˜40% of flavescent sophora root, 10-55% of stemona root, 10˜35% of cnidium fruit, 5˜60% of portulaca, 10˜40% of gentian root and 5˜60% of goldthread root.
12. A herbal medicine as claimed in claim 7, wherein the herbal medicine comprises 10˜70% of goldenlarch bark, 5˜50% of goldthread root, 5˜50% of flavescent sophora root, 5˜60% of stemona root, 5˜60% of white cloves, 5˜40% of pricklyash peel, 5˜70% of oldenlandia and 5˜30% of portulaca.
13. A herbal medicine as claimed in claim 7, wherein the herbal medicine comprises 10˜70% of poria, 1˜30% of pinellia tuber, 5˜50% of pilose asiabell root, 1˜50% of immature bitter orange, 5˜40% of green tangerine orange peel, 1˜30% of atractylodes rhizome, 1˜25% of fresh ginger, 5˜40% of oldenlandia and 5˜40% lonicera japonica flower.
14. A herbal medicine as claimed in claim 7, wherein the herbal medicine comprises 5˜50% of Chinese yam, 5˜65% of pueraria root, 10˜70% of poria, 5˜75% of dried rehmannia root, 5˜65% of wolfberry fruit, 5˜50% of pollen, 5˜40% of rhizoma alismatis, 1˜35% of mulberry leaf, 1˜50% of lotus leaf, 1˜50% of atractylodes rhizome, 0˜35% of cherokee rose-hip and 5˜65% of black plum.
15. A herbal medicine as claimed in claim 7, wherein the herbal medicine comprises 5˜30% of oriental wormwood, 1˜25% of red sage root, 1˜30% of dandelion herb, 2˜25% of bupleurum root, 1˜20% of scutellaria root, 0˜40% of oldenlandia, 0˜35% of pollen, 0˜30% of wolfberry fruit, 1˜25% of mulberry leaf, and 1˜25% of rhizoma alismatis.
16. A herbal medicine as claimed in claim 7, wherein the herbal medicine comprises 1˜30% of tetrandra root, 1˜20% of ginseng, 5˜40% of cinnamon twig, 5˜30% of plaster stone, 5˜30% of lotus leaf, 5˜30% of mulberry leaf, 1˜25% of immature bitter orange and 1˜40% of Cherokee rose-hip.
17. A herbal medicine as claimed in claim 7, wherein the herbal medicine comprises 5˜30% of ginseng, 5˜30% of astragahis root, 5˜40% of lotus leaf, 5˜35% of schizonepeta and 5˜25% of tetrandra root.
US08/359,693 1993-12-21 1994-12-20 Preparation of herbal medicines by using a multi-enzyme system, herbal medicines prepared and their uses Expired - Fee Related US5595743A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN93120926.9 1993-12-21
CN93120926A CN1102993A (en) 1993-12-21 1993-12-21 Method for making Chinese medicine herbs preparation by polyenzyme system

Publications (1)

Publication Number Publication Date
US5595743A true US5595743A (en) 1997-01-21

Family

ID=4993471

Family Applications (1)

Application Number Title Priority Date Filing Date
US08/359,693 Expired - Fee Related US5595743A (en) 1993-12-21 1994-12-20 Preparation of herbal medicines by using a multi-enzyme system, herbal medicines prepared and their uses

Country Status (3)

Country Link
US (1) US5595743A (en)
JP (1) JPH0834742A (en)
CN (1) CN1102993A (en)

Cited By (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766614A (en) * 1997-03-20 1998-06-16 Yong; Liu Burn treatment compositions containing herbal mix
WO1999022750A1 (en) * 1996-08-19 1999-05-14 Eitan Balassyano Vision improving eye solution
US5908628A (en) * 1998-05-01 1999-06-01 Hou; Liping Compositions with analgesic, antipyretic and antiinflammatory properties
US5958417A (en) * 1996-10-24 1999-09-28 Hsu; Chau-Shin Herbal combinations
US6060062A (en) * 1997-06-26 2000-05-09 Fowler; Pearline Liquid composition for the topical application to relieve arthritic pain
US6077512A (en) * 1993-10-13 2000-06-20 Chen; Ren-Rong Externally-applied medicine for curing black foot disease
US6093403A (en) * 1997-08-01 2000-07-25 Phytocell Research, Inc. Sugar imbalance and diabetes treating herbal formulation
US6210738B1 (en) 1999-04-23 2001-04-03 E Excel Internatioanal Inc. Freeze-dried ginseng berry tea
US6238672B1 (en) 1999-04-23 2001-05-29 E. Excel International Inc. Dietary supplements containing dehydrated cactus fruit juice and ginseng berry juice
US6350476B1 (en) 2000-05-22 2002-02-26 Shanxi Zhengzhon Pharmaceutical Co., Ltd. Herbal chinese joint complex
US6383525B1 (en) 2000-12-14 2002-05-07 Globoasia L.L.C. Herbal compositions for treating immunological disorders
US6383524B2 (en) 2000-06-01 2002-05-07 Theralife, Inc. Compositions and methods for enhancing therapeutic effects
US6485752B1 (en) 2000-10-23 2002-11-26 Otto Torbjorn Hansen Composition and method for alleviating joint pain and stiffness
US6524626B2 (en) 1999-04-23 2003-02-25 E Excel International, Inc. Ginseng berry topical products
US6537581B2 (en) 2000-06-01 2003-03-25 Theralife, Inc. Compositions and methods for treating eye discomfort
US6576286B1 (en) 1999-04-23 2003-06-10 E Excel International Cactus fruit drinks and food products
EP1338303A1 (en) * 2002-02-20 2003-08-27 Katrin Kilb Detoxifying phytotherapeutic composition from two plant extracts and process for preparing the same
US6676686B2 (en) 2000-04-25 2004-01-13 Harumi Naganuma Noninvasive detection and activation of the lymphatic system in treating disease and alleviating pain
US20040028751A1 (en) * 2000-12-12 2004-02-12 Tatsumasa Mae Compositions for preventing or ameliorating multiple risk factor syndromes
US20040033276A1 (en) * 2002-07-27 2004-02-19 Jeong-Chan Ra Coating composition for cereals having a preventive or treating effect on diabetes and cereals coated thereby
US20040058015A1 (en) * 2000-06-01 2004-03-25 Yuanjin Tao Compositions and methods for treating eye discomfort and eye disease
US20040105849A1 (en) * 2002-11-25 2004-06-03 Kaloidis Antonia C. Treatment for SMA disease
WO2004096252A1 (en) * 2003-04-25 2004-11-11 Primavera Biosciences, Inc. Compositions and methods for weight loss
US20050058728A1 (en) * 2003-09-12 2005-03-17 Randolph Russell K. Cytokine modulators and related method of use
US20050069576A1 (en) * 2003-09-25 2005-03-31 Robert Mills Mahonia aquifolium extract, extraction process and pharmaceutical composition containing the same
US20050220904A1 (en) * 2003-03-28 2005-10-06 Zuguang Zhang Pharmaceutical composition for treatment of bph and preparation thereof
US20060029686A1 (en) * 2003-09-12 2006-02-09 Access Business Group International Llc Cytokine modulators and related methods of use
US20060134246A1 (en) * 2004-12-22 2006-06-22 Wang Helen H Use of alisma orientale in cosmetics and compositions thereof
US20060286054A1 (en) * 2005-06-15 2006-12-21 Apollo Pharmaceutical, Inc. Pharmaceutical compositions for the treatment of psoriasis
DE102005042139A1 (en) * 2005-09-05 2007-03-08 Ingrid Priebe Use of gentian root mash and appropriate remedies
US20070141012A1 (en) * 2002-07-31 2007-06-21 Melaleuca, Inc. Skin Care Compositions
US20070196447A1 (en) * 2006-02-01 2007-08-23 Weg Stuart L Use Of Antifungal Compositions To Treat Upper Gastrointestinal Conditions
RU2311188C2 (en) * 2002-02-27 2007-11-27 Липин ЯН Use of summary cumarins of fruit cnidum in preparation of therapeutical drugs for treatment of psoriasis
KR100778107B1 (en) 2006-07-14 2007-11-29 한국식품연구원 Method for producing a polymer polysaccharide containing arabino galactan from March
US20090028896A1 (en) * 2004-04-26 2009-01-29 Primavera Biosciences, Inc. Compositions and method for weight loss
WO2010068304A1 (en) * 2008-12-10 2010-06-17 Freelife International, Inc. Formulations and methods for maintaining normal hormone levels
US7758903B2 (en) 2003-09-12 2010-07-20 Access Business Group International Llc Cytokine modulators and related methods of use
US20100303974A1 (en) * 2009-05-27 2010-12-02 Sheng-Pu Pharmaceutic Co., Ltd Method of preparing an extract from multiple botanic herbs by an ultrasonic way under a low temperature
US20110059190A1 (en) * 2008-05-06 2011-03-10 Finzelberg Gmbh & Co. Kg Cistus extract containing enriched secondary plant ingredients
US20110135721A1 (en) * 2007-12-21 2011-06-09 Finzelberg Gmbh & Co., Kg Preparations with rosehip extracts, and method of producing rosehip extracts
US20120077761A1 (en) * 2009-06-12 2012-03-29 Generex Pharmaceuticals, Inc Compositions and methods for the prevention and treatment of coronary heart diseases
KR101155145B1 (en) 2010-03-04 2012-06-12 한국식품연구원 Composition for improving blood flow, preparation method thereof and health functional foods comprising thereof
US20130224317A1 (en) * 2010-10-26 2013-08-29 Fhg Corporation D/B/A Integrity Nutraceuticals Methods and materials for reducing multiple risk factors associated with the metabolic syndrome
US9427431B2 (en) 1998-04-09 2016-08-30 Johns Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
US9440988B2 (en) 1998-04-09 2016-09-13 John Hopkins University School Of Medicine Regulators of the hedgehog pathway, compositions and uses related thereto
CN109913427A (en) * 2017-12-29 2019-06-21 南京中医药大学 Rhizoma alismatis squalene epoxidase enzymes and its application
CN110892951A (en) * 2019-11-22 2020-03-20 中国农业大学 Method for preparing piglet anti-diarrhea feed by using anaerobic enzymolysis composite traditional Chinese medicine residues
CN115634233A (en) * 2022-11-09 2023-01-24 陕西师范大学 Application of glycyrrhiza polysaccharide in preparation of product for relieving triptolide toxicity
CN119280302A (en) * 2024-12-13 2025-01-10 齐鲁工业大学(山东省科学院) A kind of compound celecoxib capsule and preparation method thereof
CN120381498A (en) * 2025-06-30 2025-07-29 吉林医药学院 An anti-acne probiotic fermented product of Stemona tuberosa and its preparation method and application

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000103718A (en) * 1998-09-28 2000-04-11 Pola Chem Ind Inc Composition for improving activity of living body
EP2269621B1 (en) * 2008-03-31 2017-12-27 Shiseido Company, Ltd. Cinnamonum extract for treating photoaging
CN104257767B (en) * 2014-09-19 2017-05-17 西藏藏真堂藏药产业有限公司 Method for extracting active ingredients of rheum australe and application thereof
CN104522683A (en) * 2014-12-19 2015-04-22 无限极（中国）有限公司 Application of Chinese angelica polypeptide with effects of resisting oxidization and delaying ageing in preparation of food
JP6764690B2 (en) 2016-05-23 2020-10-07 オイレス工業株式会社 Rotary damper
CN107041553A (en) * 2017-03-28 2017-08-15 曲靖师范学院 The method that the smelly ginseng aerial part of three kinds of enzyme mixed hydrolysis extracts soluble component
KR102283756B1 (en) * 2019-08-23 2021-07-30 하헌용 Cosmetic compositon comprising hedyotis diffusa extract treated with complex exzyme

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202122A (en) * 1989-10-30 1993-04-13 Humanetics Corporation Process for enhancing the hypocholesterolemic effect of edible pulp and the product obtained thereby

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202122A (en) * 1989-10-30 1993-04-13 Humanetics Corporation Process for enhancing the hypocholesterolemic effect of edible pulp and the product obtained thereby

Cited By (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077512A (en) * 1993-10-13 2000-06-20 Chen; Ren-Rong Externally-applied medicine for curing black foot disease
WO1999022750A1 (en) * 1996-08-19 1999-05-14 Eitan Balassyano Vision improving eye solution
US5958417A (en) * 1996-10-24 1999-09-28 Hsu; Chau-Shin Herbal combinations
US5766614A (en) * 1997-03-20 1998-06-16 Yong; Liu Burn treatment compositions containing herbal mix
US6060062A (en) * 1997-06-26 2000-05-09 Fowler; Pearline Liquid composition for the topical application to relieve arthritic pain
US6093403A (en) * 1997-08-01 2000-07-25 Phytocell Research, Inc. Sugar imbalance and diabetes treating herbal formulation
US9440988B2 (en) 1998-04-09 2016-09-13 John Hopkins University School Of Medicine Regulators of the hedgehog pathway, compositions and uses related thereto
US9427431B2 (en) 1998-04-09 2016-08-30 Johns Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
US5908628A (en) * 1998-05-01 1999-06-01 Hou; Liping Compositions with analgesic, antipyretic and antiinflammatory properties
WO2000050055A1 (en) * 1999-02-25 2000-08-31 Phytocell Research, Inc. Sugar imbalance and diabetes treating herbal formulation
US6238672B1 (en) 1999-04-23 2001-05-29 E. Excel International Inc. Dietary supplements containing dehydrated cactus fruit juice and ginseng berry juice
US6524626B2 (en) 1999-04-23 2003-02-25 E Excel International, Inc. Ginseng berry topical products
US6210738B1 (en) 1999-04-23 2001-04-03 E Excel Internatioanal Inc. Freeze-dried ginseng berry tea
US6576286B1 (en) 1999-04-23 2003-06-10 E Excel International Cactus fruit drinks and food products
US6676686B2 (en) 2000-04-25 2004-01-13 Harumi Naganuma Noninvasive detection and activation of the lymphatic system in treating disease and alleviating pain
US6350476B1 (en) 2000-05-22 2002-02-26 Shanxi Zhengzhon Pharmaceutical Co., Ltd. Herbal chinese joint complex
US6521269B2 (en) 2000-06-01 2003-02-18 Theralife, Inc. Compositions and methods for enhancing therapeutic effects
US6537581B2 (en) 2000-06-01 2003-03-25 Theralife, Inc. Compositions and methods for treating eye discomfort
US20030165583A1 (en) * 2000-06-01 2003-09-04 Yuanjin Tao Compositions and methods for enhancing therapeutic effects
US6383524B2 (en) 2000-06-01 2002-05-07 Theralife, Inc. Compositions and methods for enhancing therapeutic effects
US20040058015A1 (en) * 2000-06-01 2004-03-25 Yuanjin Tao Compositions and methods for treating eye discomfort and eye disease
US6485752B1 (en) 2000-10-23 2002-11-26 Otto Torbjorn Hansen Composition and method for alleviating joint pain and stiffness
US20040028751A1 (en) * 2000-12-12 2004-02-12 Tatsumasa Mae Compositions for preventing or ameliorating multiple risk factor syndromes
US8071141B2 (en) 2000-12-12 2011-12-06 Kaneka Corporation Compositions for preventing or ameliorating multiple risk factor syndromes
US20050287233A1 (en) * 2000-12-12 2005-12-29 Tatsumasa Mae Compositions for preventing or ameliorating multiple risk factor syndromes
US6383525B1 (en) 2000-12-14 2002-05-07 Globoasia L.L.C. Herbal compositions for treating immunological disorders
EP1338303A1 (en) * 2002-02-20 2003-08-27 Katrin Kilb Detoxifying phytotherapeutic composition from two plant extracts and process for preparing the same
RU2311188C2 (en) * 2002-02-27 2007-11-27 Липин ЯН Use of summary cumarins of fruit cnidum in preparation of therapeutical drugs for treatment of psoriasis
US20040033276A1 (en) * 2002-07-27 2004-02-19 Jeong-Chan Ra Coating composition for cereals having a preventive or treating effect on diabetes and cereals coated thereby
US20070141012A1 (en) * 2002-07-31 2007-06-21 Melaleuca, Inc. Skin Care Compositions
US20040105849A1 (en) * 2002-11-25 2004-06-03 Kaloidis Antonia C. Treatment for SMA disease
US20050220904A1 (en) * 2003-03-28 2005-10-06 Zuguang Zhang Pharmaceutical composition for treatment of bph and preparation thereof
US7556828B2 (en) * 2003-03-28 2009-07-07 Zuguang Zhang Pharmaceutical composition for treatment of BPH and preparation thereof
WO2004096252A1 (en) * 2003-04-25 2004-11-11 Primavera Biosciences, Inc. Compositions and methods for weight loss
US20050058728A1 (en) * 2003-09-12 2005-03-17 Randolph Russell K. Cytokine modulators and related method of use
US20060029686A1 (en) * 2003-09-12 2006-02-09 Access Business Group International Llc Cytokine modulators and related methods of use
US7838050B2 (en) 2003-09-12 2010-11-23 Access Business Group International Llc Cytokine modulators and related method of use
US7758903B2 (en) 2003-09-12 2010-07-20 Access Business Group International Llc Cytokine modulators and related methods of use
US7758902B2 (en) 2003-09-12 2010-07-20 Access Business Group International Llc Cytokine modulators and related methods of use
US20070148226A1 (en) * 2003-09-25 2007-06-28 Prime Pharmaceutical Corporation Mahonia aquifolim extract, extraction process and pharmaceutical composition containing the same
US20050069576A1 (en) * 2003-09-25 2005-03-31 Robert Mills Mahonia aquifolium extract, extraction process and pharmaceutical composition containing the same
US7621740B2 (en) 2003-09-25 2009-11-24 Prime Pharmaceutical Corporation Mahonia aquifolium extract, extraction process and pharmaceutical composition containing the same
US7205006B2 (en) 2003-09-25 2007-04-17 Prime Pharmaceutical Corporation Mahonia aquifolium extract, extraction process and pharmaceutical composition containing the same
US20090028896A1 (en) * 2004-04-26 2009-01-29 Primavera Biosciences, Inc. Compositions and method for weight loss
US20080268080A1 (en) * 2004-12-22 2008-10-30 Avon Products, Inc. Use of alisma orientale in cosmetics and compositions thereof
US20060134246A1 (en) * 2004-12-22 2006-06-22 Wang Helen H Use of alisma orientale in cosmetics and compositions thereof
US7410658B2 (en) * 2004-12-22 2008-08-12 Avon Products, Inc. Use of Alisma orientale in cosmetics and compositions thereof
US20060286054A1 (en) * 2005-06-15 2006-12-21 Apollo Pharmaceutical, Inc. Pharmaceutical compositions for the treatment of psoriasis
DE102005042139A1 (en) * 2005-09-05 2007-03-08 Ingrid Priebe Use of gentian root mash and appropriate remedies
US7776831B2 (en) * 2006-02-01 2010-08-17 Weg Stuart L Use of antifungal compositions to treat upper gastrointestinal conditions
US20110008291A1 (en) * 2006-02-01 2011-01-13 Weg Stuart L Use of antifungal compositions to treat upper gastrointestinal conditions
US20070196447A1 (en) * 2006-02-01 2007-08-23 Weg Stuart L Use Of Antifungal Compositions To Treat Upper Gastrointestinal Conditions
KR100778107B1 (en) 2006-07-14 2007-11-29 한국식품연구원 Method for producing a polymer polysaccharide containing arabino galactan from March
US20110135721A1 (en) * 2007-12-21 2011-06-09 Finzelberg Gmbh & Co., Kg Preparations with rosehip extracts, and method of producing rosehip extracts
US9937215B2 (en) * 2007-12-21 2018-04-10 Finzelberg Gmbh & Co., Kg Preparations with rosehip extracts, and method of producing rosehip extracts
AU2008339944B2 (en) * 2007-12-21 2014-05-01 Finzelberg Gmbh & Co. Kg Preparations with rosehip extracts, and method of producing rosehip extracts
US9173912B2 (en) 2008-05-06 2015-11-03 Finzelberg Gmbh & Co. Kg Cistus extract containing enriched secondary plant ingredients
US20110059190A1 (en) * 2008-05-06 2011-03-10 Finzelberg Gmbh & Co. Kg Cistus extract containing enriched secondary plant ingredients
WO2010068304A1 (en) * 2008-12-10 2010-06-17 Freelife International, Inc. Formulations and methods for maintaining normal hormone levels
US20100303974A1 (en) * 2009-05-27 2010-12-02 Sheng-Pu Pharmaceutic Co., Ltd Method of preparing an extract from multiple botanic herbs by an ultrasonic way under a low temperature
US9050277B2 (en) 2009-06-12 2015-06-09 Generex Pharmaceuticals, Inc. Combined Geum japonicum and Centella asiatica extracts for the therapeutic treatment of heart failure
US9950019B2 (en) 2009-06-12 2018-04-24 Generex Pharmaceuticals, Inc. Compositions and methods for the prevention and treatment of brain diseases and conditions
US9283255B2 (en) 2009-06-12 2016-03-15 Generex Pharmaceuticals, Inc. Compositions and methods for the prevention and treatment of red blood cell coagulation
US9629884B2 (en) 2009-06-12 2017-04-25 Generex Pharmaceuticals, Inc. Compositions and methods for increasing lifespan and health span
US20120077761A1 (en) * 2009-06-12 2012-03-29 Generex Pharmaceuticals, Inc Compositions and methods for the prevention and treatment of coronary heart diseases
KR101155145B1 (en) 2010-03-04 2012-06-12 한국식품연구원 Composition for improving blood flow, preparation method thereof and health functional foods comprising thereof
US9278104B2 (en) * 2010-10-26 2016-03-08 In Ingredients, Inc. Methods and materials for reducing multiple risk factors associated with the metabolic syndrome
US20130224317A1 (en) * 2010-10-26 2013-08-29 Fhg Corporation D/B/A Integrity Nutraceuticals Methods and materials for reducing multiple risk factors associated with the metabolic syndrome
CN109913427A (en) * 2017-12-29 2019-06-21 南京中医药大学 Rhizoma alismatis squalene epoxidase enzymes and its application
CN109913427B (en) * 2017-12-29 2022-07-01 南京中医药大学 Alisma orientale squalene epoxidase and application thereof
CN110892951A (en) * 2019-11-22 2020-03-20 中国农业大学 Method for preparing piglet anti-diarrhea feed by using anaerobic enzymolysis composite traditional Chinese medicine residues
CN115634233A (en) * 2022-11-09 2023-01-24 陕西师范大学 Application of glycyrrhiza polysaccharide in preparation of product for relieving triptolide toxicity
CN115634233B (en) * 2022-11-09 2024-05-14 陕西师范大学 Application of licorice polysaccharide in preparation of triptolide toxicity relieving product
CN119280302A (en) * 2024-12-13 2025-01-10 齐鲁工业大学(山东省科学院) A kind of compound celecoxib capsule and preparation method thereof
CN120381498A (en) * 2025-06-30 2025-07-29 吉林医药学院 An anti-acne probiotic fermented product of Stemona tuberosa and its preparation method and application

Also Published As

Publication number Publication date
CN1102993A (en) 1995-05-31
JPH0834742A (en) 1996-02-06

Similar Documents

Publication Publication Date Title
US5595743A (en) Preparation of herbal medicines by using a multi-enzyme system, herbal medicines prepared and their uses
KR101445010B1 (en) Antiphlogistic, antioncotic and analgesic chinese herbal composition, preparative method and usage thereof
CN102697035A (en) Cordyceps anti-aging pellet
CN101332277A (en) Preparation method of first-aid liquid for treating whole blood elevation
KR20160064966A (en) Medical composition and applications thereof used for secondary chemotherapy drugs
US20090226544A1 (en) Pharmaceutical Compound For Treating Inflammation, Pain, Arthritis And Spinitis, And Proliferating Osteoblastic Cell And Method For Producing Thereof
RU2419449C1 (en) Medication for treatment of patients with drug hepatitis
CN109998009A (en) A kind of solid beverage of Chinese chestnut peptide and preparation method thereof
RU2147239C1 (en) General tonic nonspecific immunomodulating agent
RU2058152C1 (en) Agent for chronic prostatitis treatment
EP0506773B1 (en) A stimulator of vascular endothelial cells and use thereof
CN111298061B (en) Traditional Chinese medicine composition for clearing heat and detoxicating, removing stasis and resolving masses and preparation method thereof
CN107982510A (en) A kind of coltsfoot frondosa oral liquid for helping to give up smoking and preparation method thereof
CN108077485A (en) A kind of blue or green money willow herbal tea and preparation method thereof
CN114288354A (en) Medicinal liquor for treating helicobacter pylori and preparation method thereof
CN114010755A (en) Preparation for controlling uric acid and preparation method thereof
CN100363046C (en) Prepn for treating fatty liver and alcoholic liver and its prepn process
CN120241876B (en) Composition containing ginseng extract and preparation method and application thereof
CN118831137B (en) A Chinese medicine composition for treating cardiovascular and cerebrovascular diseases and its preparation method
CN100448466C (en) Medicine for preventing and adjuvant treating cancer and its preparation method
JP2003171306A (en) Physiologically active composition and method for producing the same
CN1179328A (en) Medicine and food for treating diabetes and producing method thereof
CN119185417B (en) Composition for promoting blood circulation, reducing turbidity and preventing myocardial infarction, as well as preparation method and application thereof
KR20000061656A (en) Chinese medicine for cancer treatment
CN116211993B (en) Composition for treating senile chronic disease and its preparation method

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FPAY Fee payment

Year of fee payment: 4

SULP Surcharge for late payment
REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20050121